{"FP": [{"generated": ["Progressive mobilization"], "gold": [], "text": "Progressive mobilization of the patient was obtained as well as a complete normalization of the laboratory findings."}, {"generated": ["after the fourth course"], "gold": [], "text": "We describe here the unexpected onset of heavy toxicity including rhabdomyolysis after the fourth course of trabectedin in a patient with retroperitoneal liposarcoma who at the same time was taking an alternative herbal medicine suspected of triggering this adverse event."}, {"generated": ["early in the morning"], "gold": [], "text": "The clinical pharmacist recommended dose increases of carbidopa-levodopa to help control his tremors still present early in the morning (Figure 1)."}, {"generated": ["for the past two decades"], "gold": ["the past two decades"], "text": "During the past two decades, the world has witnessed an increased rate of conventional medicines integrated with CAM for treatment."}, {"generated": ["to date"], "gold": [], "text": "To date an increasing number of studies in evaluating HDIs have been reported [11]."}, {"generated": ["over the last decade"], "gold": [], "text": "With the boom in conventional therapeutic drugs, the utilization of herbal remedies sometimes in combination with other medications has increased tremendously over the last decade [1,2]."}, {"generated": ["chronically"], "gold": [], "text": "The TDI effects of these herbals is felt when patients chronically use them because sufficient intermediary metabolites may be generated and this can be deleterious to consumers concomitantly taking conventional medications, as stated earlier."}, {"generated": ["96 h after dose"], "gold": [], "text": "Four of these metabolites (6\u03b1, 6\u03b2, 7\u03b1 and 7\u03b2 positions) have been identified in urine, which represented 1, 20, 6 and 14% of urinary recovered dose 96\u2009h after dose, respectively (Oida et al., 1985)."}, {"generated": ["2 days after", "the day before"], "gold": [], "text": "All participants were asked not to drink caffeine-containing beverages and to refrain from grapefruit from the day before until 2 days after taking gliclazide."}, {"generated": ["2 days after", "the day before"], "gold": [], "text": "All participants were asked not to drink caffeine-containing beverages and to refrain from grapefruit from the day before until 2 days after taking gliclazide."}, {"generated": ["despite discontinuation"], "gold": [], "text": "This case culminated in liver failure despite discontinuation of the herbal supplement [4]."}, {"generated": ["currently"], "gold": [], "text": "At present, our current studies at the pharmacokinetic level may not be able to explain this problem strongly."}, {"generated": ["over 30 min"], "gold": [], "text": "GRT and FRE inhibited the reaction rate of CYP2C8, CYP2C9, and CYP3A4 as measured over 30 min (Figure 2a\u2013c)."}, {"generated": ["for 12 weeks"], "gold": [], "text": "2)."}, {"generated": ["until analysis"], "gold": [], "text": "Subsequently, plasma was separated and stored at \u221220\u00b0C until analysis."}, {"generated": ["in cycle 2", "in cycle 1"], "gold": [], "text": "Statistical analysis  For each patient, the values of AUC0\u2013\u221e, t1/2 and Cmax of docetaxel in cycle 1 (before E. purpurea) were compared with values obtained in cycle 2 (after E. purpurea)."}, {"generated": ["in cycle 2", "in cycle 1"], "gold": [], "text": "Statistical analysis  For each patient, the values of AUC0\u2013\u221e, t1/2 and Cmax of docetaxel in cycle 1 (before E. purpurea) were compared with values obtained in cycle 2 (after E. purpurea)."}, {"generated": ["on Day 15"], "gold": [], "text": "Compared to the single administration of digoxin (Day 1), the concomitant administration of digoxin and GTC was associated with a significant reduction in systemic exposure of digoxin (Day 15): AUC The concentration\u2013time profiles of EC, EGC, ECG, and EGCG and the pharmacokinetics parameters are presented in Figure 4 and Table 3."}, {"generated": ["Day 1"], "gold": [], "text": "To identify the effect of ABCB1 genotype on the pharmacokinetic alteration of digoxin by GTC, we compared the percentage changes from Day 1 (digoxin alone treatment) of AUC This study investigated the effect of GTC on the pharmacokinetics of digoxin."}, {"generated": ["2 h"], "gold": [], "text": "Pharmacokinetic studies started 2 h after the last RGE treatment."}, {"generated": ["at room temperature"], "gold": [], "text": "; 3.5\u2009\u03bcm) at room temperature."}, {"generated": ["10 min"], "gold": [], "text": "After centrifuging at 3500\u2009rpm for 10\u2009min, the supernatant was obtained and frozen at \u221240\u2009\u00b0C until analysis."}, {"generated": ["half-life"], "gold": [], "text": "The half-life (t Experimental values are expressed as mean\u2009\u00b1\u2009SD."}, {"generated": ["over the concentration range of 1\u2013500 ng/mL"], "gold": [], "text": "Linearity for AC was obtained over the concentration range of 1\u2013500\u2009ng/mL."}, {"generated": ["after the administration"], "gold": [], "text": "used the duration of QRS interval prolongation, ventricular precontraction, ventricular tachycardia, and ventricular fibrillation as markers of arrhythmia to study the effects of C. pinnatifida Bunge (Shanzha) extract on digoxin-induced arrhythmias, and the results showed that the ventricular arrhythmias in the digoxin-induced experimental group of rats all decreased after the administration of C. pinnatifida Bunge (Shanzha) extract, indicating that the flavonoid glycoside and flavane polymers in C. pinnatifida Bunge (Shanzha) extract can antagonize digoxin-induced arrhythmias (Li and Huang, 2016), which may be related to their ability to dilate blood vessels, lower blood pressure, slow down the heart rhythm, and improve the cardiovascular system (Zhang et al., 2021)."}, {"generated": ["at ambient temperature"], "gold": [], "text": "Plates were thawed at ambient temperature."}, {"generated": ["30-minute preincubations"], "gold": ["30-minute"], "text": "Potential TDI of P450 enzyme activity by CAW-R61J was determined using the shift in IC50 values between 30-minute preincubations in the presence and absence of NADPH."}, {"generated": ["for 12 weeks"], "gold": [], "text": "2 above (substituting logEC50 for logIC50)."}, {"generated": ["of triplicate determinations"], "gold": [], "text": "of triplicate determinations."}, {"generated": ["for 24 h"], "gold": [], "text": "Post-preparative stability was evaluated by comparing the extracted QC samples maintained in the autosampler at 6 \u00b0C for 24 h (compared with the untreated QC samples)."}, {"generated": ["1 h after oral administration"], "gold": [], "text": "Figure 2 shows the chromatograms of the blank matrix and those of fimasartan, fimasartan-amide, amlodipine, and hydrochlorothiazide spiked at the LLOQ or rat plasma samples 1 h after oral administration of fimasartan, amlodipine, and hydrochlorothiazide."}, {"generated": ["chronic"], "gold": [], "text": "However, there are several challenges associated with the chronic nature of HAART administration."}, {"generated": ["72 h"], "gold": ["for 72 h"], "text": "The material was allowed to extract for 72 h at room temperature during which supernatant was decanted every 24 h and the solid residue reconstituted in the same volume of purified water for the extraction process to be repeated."}, {"generated": ["7 \u00b1 1-day"], "gold": [], "text": "Each participant received three treatments with a 7 \u00b1 1-day washout period in-between."}, {"generated": ["per day"], "gold": [], "text": "To mimic the recommended dose based on the status of patients, AAP dose is suggested from 1000 mg to the maximum dose of 1000 mg \u00d7 4 times (8 tablets) per day for treatment of the common cold [22,23]."}, {"generated": ["in a week"], "gold": ["week"], "text": "Therefore, two simulation scenarios were used to evaluate the magnitude of any interaction, (AAP 1000 mg once daily + GGT 7680 mg once daily) and (AAP 1000 mg \u00d7 4 times daily + GGT 7680 mg once daily) in a week."}, {"generated": ["long-term"], "gold": [], "text": "Single time-point, phenotypic metabolic ratios were used to determine whether long-term supplementation of St. John\u2019s wort, garlic oil, Panax ginseng, and Ginkgo biloba affected CYP1A2, CYP2D6, CYP2E1, or CYP3A4 activity in elderly subjects."}, {"generated": ["five days"], "gold": [], "text": "Adherence to these restrictions was further emphasized five days before each probe drug administration."}, {"generated": ["during the course of the investigation"], "gold": [], "text": "[45] Go to: RESULTS General Experimental Observations  All subjects completed the study and no serious adverse events occurred during the course of the investigation."}, {"generated": ["overnight"], "gold": [], "text": "In the first phase, after an overnight fast, each subject in the respective groups received a single oral dose of 600 mg quinine sulphate tablets (Maderich Ltd, Surrey, England)."}, {"generated": ["at 1, 2, 3,4, 6, 8, 12, 24, 36 and 48 h", "just before the administration"], "gold": [], "text": "Sample collection  Venous blood samples (5ml) was collected into heparinised tubes at time zero (just before the administration of quinine sulphate tablets)) and at 1, 2, 3,4, 6, 8, 12, 24, 36 and 48 h after each participant received quinine alone or concurrently with the scheduled dose of G. kola."}, {"generated": ["at 1, 2, 3,4, 6, 8, 12, 24, 36 and 48 h", "just before the administration"], "gold": [], "text": "Sample collection  Venous blood samples (5ml) was collected into heparinised tubes at time zero (just before the administration of quinine sulphate tablets)) and at 1, 2, 3,4, 6, 8, 12, 24, 36 and 48 h after each participant received quinine alone or concurrently with the scheduled dose of G. kola."}, {"generated": ["about 9 %"], "gold": [], "text": "The AUC0\u2013\u221e of quinine was slightly reduced by about 9 %."}, {"generated": ["2 months"], "gold": [], "text": "Unfortunately, a [18 F]-fluorethylenthyrosin positron emission tomography positive residual tumor was detected 2 months after the end of radiotherapy."}, {"generated": ["at least 6 minutes"], "gold": [], "text": "Briefly, whole blood (0.5\u2009mL) was diluted twofold with freshly prepared normal saline and incubated at 37\u2009\u00b0C for at least 6\u2009min."}, {"generated": ["for 12 weeks"], "gold": [], "text": "Table 2  Pharmacokinetic parameters of S-warfarin and R-warfarin  \tMean (95% CI)\tGeometric mean ratio (90% CI)  \tWarfarin only\tWarfarin and cranberry\tWarfarin and garlic\tWarfarin and cranberry/warfarin only\tWarfarin and garlic/warfarin only S-warfarin \u2003tmax (h)\t1.4 (1.1\u20131.6)\t1.9 (1.1\u20132.7)\t1.3 (1.1\u20131.6)\tNA\tNA \u2003Cmax (\u03bcg\u2009mL\u22121)\t1.8 (1.7\u20131.9)\t1.7 (1.5\u20132.0)\t1.9 (1.5\u20132.2)\t0.94 (0.67\u20131.29)\t1.06 (0.77\u20131.47) \u2003t1/2 (h)\t38.6 (35.7\u201341.5)\t34.9 (31.0\u201338.8)\t41.2 (35.1\u201347.3)\t0.94 (0.79\u20131.12)\t0.99 (0.83\u20131.18) \u2003AUC (\u03bcg\u2009mL\u22121\u2009h)\t60.3 (54.5\u201366.1)\t63.0 (57.3\u201368.8)\t65.5 (55.3\u201375.6)\t1.04 (0.94\u20131.67)\t1.06 (0.95\u20131.19) \u2003CL/F (mL\u2009h\u22121)\t213 (193\u2013232)\t204 (183\u2013224)\t202 (175\u2013229)\t0.89 (0.80\u20130.99)\t1.05 (0.94\u20131.17) \u2003Fraction unbound (fu)\t0.010 (0.007\u20130.013)\t0.010 (0.007\u20130.014)\t0.011 (0.008\u20130.014)\t1.00 (0.75\u20131.25)\t1.12 (0.39\u20131.84)  \t \t \t \t \t  R-warfarin \u2003tmax (h)\t1.4 (1.1\u20131.6)\t1.9 (1.1\u20132.7)\t1.8 (0.7\u20132.9)\tNA\tNA \u2003Cmax (\u03bcg\u2009mL\u22121)\t1.8 (1.7\u20132.0)\t1.7 (1.5\u20131.9)\t1.9 (1.5\u20132.2)\t0.90 (0.67\u20131.21)\t1.02 (0.8\u20131.4) \u2003t1/2 (h)\t55.6 (46.2\u201365.0)\t47.7 (41.5\u201353.9)\t52.6 (47.4\u201357.9)\t0.93 (0.80\u20131.08)\t0.98 (0.84\u20131.14) \u2003AUC (\u03bcg\u2009mL\u22121\u2009h)\t108.7 (90.0\u2013127.3)\t105.8 (91.7\u2013119.9)\t105.0 (96.3\u2013113.7)\t1.0 (0.9\u20131.1)\t0.99 (0.87\u20131.13) \u2003CL/F (mL\u2009h\u22121)\t123 (106\u2013140)\t124 (109\u2013139)\t121 (112\u2013131)\t0.87 (0.75\u20130.99)\t0.96 (0.84\u20131.11) \u2003Fraction unbound (fu)\t0.006 (0.004\u20130.007)\t0.005 (0.004\u20130.007)\t0.006 (0.004\u20130.007)\t0.95 (0.72\u20131.18)\t1.04 (0.80\u20131.29) Open in a separate window Abbreviations: AUC, area under the plasma concentration\u2013time curve; CI, confidence interval; CL, clearance; CL/F, apparent clearance; Cmax, maximum concentration; F, bioavailability; NA, not applicable; tmax, time to Cmax."}, {"generated": ["yet"], "gold": [], "text": "Current address: Drug Metabolism and Pharmacokinetics, Covance Laboratories Inc., Madison, WI, USA Patients commonly take complementary medicines in conjunction with warfarin yet evidence supporting the safety or the risk of a herb\u2013drug interaction is lacking."}, {"generated": ["for 14 days"], "gold": ["14 subsequent days"], "text": "Daily before going to bed, participants took two tablets, with 500\u2009mg valerian extract each (extraction solvent ethanol 70%, valerenic acid content 5.51\u2009mg/tablet), for 14 subsequent days."}, {"generated": ["over 12 weeks", "after 15 days", "every 4 weeks"], "gold": ["12 weeks", "15 days"], "text": "Haloperidol (38\u2009mg/kg bw) was applied intramuscularly once every 4 weeks over 12 weeks beginning after 15 days of treatment with valerian [51]."}, {"generated": ["over 12 weeks", "after 15 days", "every 4 weeks"], "gold": ["12 weeks", "15 days"], "text": "Haloperidol (38\u2009mg/kg bw) was applied intramuscularly once every 4 weeks over 12 weeks beginning after 15 days of treatment with valerian [51]."}, {"generated": ["over 12 weeks", "after 15 days", "every 4 weeks"], "gold": ["12 weeks", "15 days"], "text": "Haloperidol (38\u2009mg/kg bw) was applied intramuscularly once every 4 weeks over 12 weeks beginning after 15 days of treatment with valerian [51]."}, {"generated": ["for 7 days"], "gold": ["7 days"], "text": "Subjects also received rifampin (600 mg) and clarithromycin (1000 mg) for 7 days as positive controls for CYP3A induction and inhibition, respectively."}, {"generated": ["rapid improvement"], "gold": [], "text": "After venlafaxine discontinuation, there was rapid improvement, with regression of the radiological abnormalities and normalization of the LVEF."}, {"generated": ["hours", "after drug discontinuation", "months"], "gold": ["hours to months"], "text": "Although DIP can occur from hours to months after the beginning of treatment, Another typical feature of DIP is its reversibility after drug discontinuation."}, {"generated": ["hours", "after drug discontinuation", "months"], "gold": ["hours to months"], "text": "Although DIP can occur from hours to months after the beginning of treatment, Another typical feature of DIP is its reversibility after drug discontinuation."}, {"generated": ["hours", "after drug discontinuation", "months"], "gold": ["hours to months"], "text": "Although DIP can occur from hours to months after the beginning of treatment, Another typical feature of DIP is its reversibility after drug discontinuation."}, {"generated": ["for a long period"], "gold": [], "text": "However, further research is needed on the safety of RHC intake for a long period in large-scale menopausal subjects."}, {"generated": ["10 min"], "gold": [], "text": "After centrifugation of the blood samples at 16,000\u00d7 g for 10 min, aliquots (50 \u03bcL each) of plasma samples were stored at \u221280 \u00b0C until the analysis of ginsenosides and valsartan."}, {"generated": ["0.17 h", "0.67 h", "4 h", "0.33 h", "1.5 h", "8 h", "2 h", "24 h", "48 h"], "gold": [], "text": "Blood samples were collected via the retro-orbital vein at 0.17, 0.33, 0.67, 1.5, 2, 4, 8, 24, and 48 h after valsartan dosing."}, {"generated": ["0.17 h", "0.67 h", "4 h", "0.33 h", "1.5 h", "8 h", "2 h", "24 h", "48 h"], "gold": [], "text": "Blood samples were collected via the retro-orbital vein at 0.17, 0.33, 0.67, 1.5, 2, 4, 8, 24, and 48 h after valsartan dosing."}, {"generated": ["0.17 h", "0.67 h", "4 h", "0.33 h", "1.5 h", "8 h", "2 h", "24 h", "48 h"], "gold": [], "text": "Blood samples were collected via the retro-orbital vein at 0.17, 0.33, 0.67, 1.5, 2, 4, 8, 24, and 48 h after valsartan dosing."}, {"generated": ["0.17 h", "0.67 h", "4 h", "0.33 h", "1.5 h", "8 h", "2 h", "24 h", "48 h"], "gold": [], "text": "Blood samples were collected via the retro-orbital vein at 0.17, 0.33, 0.67, 1.5, 2, 4, 8, 24, and 48 h after valsartan dosing."}, {"generated": ["0.17 h", "0.67 h", "4 h", "0.33 h", "1.5 h", "8 h", "2 h", "24 h", "48 h"], "gold": [], "text": "Blood samples were collected via the retro-orbital vein at 0.17, 0.33, 0.67, 1.5, 2, 4, 8, 24, and 48 h after valsartan dosing."}, {"generated": ["0.17 h", "0.67 h", "4 h", "0.33 h", "1.5 h", "8 h", "2 h", "24 h", "48 h"], "gold": [], "text": "Blood samples were collected via the retro-orbital vein at 0.17, 0.33, 0.67, 1.5, 2, 4, 8, 24, and 48 h after valsartan dosing."}, {"generated": ["0.17 h", "0.67 h", "4 h", "0.33 h", "1.5 h", "8 h", "2 h", "24 h", "48 h"], "gold": [], "text": "Blood samples were collected via the retro-orbital vein at 0.17, 0.33, 0.67, 1.5, 2, 4, 8, 24, and 48 h after valsartan dosing."}, {"generated": ["0.17 h", "0.67 h", "4 h", "0.33 h", "1.5 h", "8 h", "2 h", "24 h", "48 h"], "gold": [], "text": "Blood samples were collected via the retro-orbital vein at 0.17, 0.33, 0.67, 1.5, 2, 4, 8, 24, and 48 h after valsartan dosing."}, {"generated": ["0.17 h", "0.67 h", "4 h", "0.33 h", "1.5 h", "8 h", "2 h", "24 h", "48 h"], "gold": [], "text": "Blood samples were collected via the retro-orbital vein at 0.17, 0.33, 0.67, 1.5, 2, 4, 8, 24, and 48 h after valsartan dosing."}, {"generated": ["after 1-week"], "gold": ["1-week"], "text": "Plasma concentration-time profiles of the ginsenosides (A) Rb1, (B) Rb2, (C) Rc, (D) Rd, (E) PPD, and (F) PPT in the rat plasma after 1-week repeated administration of red ginseng extract (RGE)."}, {"generated": ["from 0 to 48 h"], "gold": [], "text": "AUC: area under the plasma concentration-time curve from 0 to 48 h C Pharmacokinetic parameters of valsartan and Rc following intravenous injection of valsartan at a dose of 1 mg/kg in rats."}, {"generated": ["\u00b11 day"], "gold": ["\u00b11\u00a0day"], "text": "For each visit, a deviation of\u00a0\u00b11\u00a0day was permitted."}, {"generated": ["markedly"], "gold": [], "text": "Furthermore, it decreases insulin and blood glucose markedly [17]."}, {"generated": ["about 4 h"], "gold": [], "text": "One mL of methanolic extract (5 mg/mL in acetone-water solution) was mixed with 200 \u00b5L of Folin-Ciocalteau reagent and 1 mL of 2% Na Total flavonoids were determined using the AlCl The herbal mixture powder (120 g) was exposed to hydrodistillation using a Clevenger type apparatus for about 4 h. Then, the obtained dark yellow oil was dried over anhydrous sodium sulfate, measured, and stored in a dark glass at 4 \u00b0C for further analyses."}, {"generated": ["longer follow-up"], "gold": [], "text": "We recommend that further research should be undertaken regarding the effects of herbal mixtures on hormonal factors of PCOS women such as sexual hormones in both proliferative and secretory phases, and lipid profile in a longer follow-up."}, {"generated": ["at the approved dosage"], "gold": [], "text": "Thus, at the approved dosage of darunavir-ritonavir, darunavir concentrations at the end of the dosing interval remain well above the concentration needed to inhibit replication of HIV strains (20; V. Sekar, S. Spinosa-Guzman, E. Lefebvre, and R. Hoetelmans, presented at the 16th International AIDS Conference, 2006)."}, {"generated": ["on days 0", "on days 28", "on days 14"], "gold": [], "text": "Safety was evaluated by clinical interview and physical examination and by laboratory assessment (blood counts, chemistry, CD4+ T-cell count, and HIV-1 RNA load) on days 0, 14, and 28."}, {"generated": ["on days 0", "on days 28", "on days 14"], "gold": [], "text": "Safety was evaluated by clinical interview and physical examination and by laboratory assessment (blood counts, chemistry, CD4+ T-cell count, and HIV-1 RNA load) on days 0, 14, and 28."}, {"generated": ["on days 0", "on days 28", "on days 14"], "gold": [], "text": "Safety was evaluated by clinical interview and physical examination and by laboratory assessment (blood counts, chemistry, CD4+ T-cell count, and HIV-1 RNA load) on days 0, 14, and 28."}, {"generated": ["for 8 days"], "gold": ["for 8\u00a0days"], "text": "The following treatments were administered for 8\u00a0days each: placebo twice daily (treatment A), EGb 761\u00ae 120\u00a0mg twice daily (treatment B), and EGb 761\u00ae 240\u00a0mg in the morning and placebo in the evening (treatment C)."}, {"generated": ["120 mg twice a day"], "gold": [], "text": "Administration of EGb 761\u00ae 120\u00a0mg b.i.d."}, {"generated": ["sufficient to eventually induce", "1 week"], "gold": ["1\u00a0week"], "text": "A maximum exposure was realized with a 240-mg EGb 761\u00ae daily dose, and exposure duration was sufficient to eventually induce CYPs, as steady state for EGb 761\u00ae components was reached, and 1\u00a0week is typically sufficient to achieve full induction [35]."}, {"generated": ["sufficient to eventually induce", "1 week"], "gold": ["1\u00a0week"], "text": "A maximum exposure was realized with a 240-mg EGb 761\u00ae daily dose, and exposure duration was sufficient to eventually induce CYPs, as steady state for EGb 761\u00ae components was reached, and 1\u00a0week is typically sufficient to achieve full induction [35]."}, {"generated": ["over an 8-day period"], "gold": ["8-day period"], "text": "does not affect CYP2C19 activity when administered over an 8-day period."}, {"generated": ["3-, 4-, 6-, 8-, 10-, 12-hour intervals"], "gold": [], "text": "However, multiple-dose combination of curcumin with gliclazide produced significantly greater reduction in percent blood glucose reduction at 3-, 4-, 6-, 8-, 10-, and 12-hour intervals after treatment in normal rats and rabbits when compared with gliclazide control."}, {"generated": ["long-term"], "gold": [], "text": "Patients on antiepileptic therapy are usually on a long-term basis."}, {"generated": ["approximately 15 minutes"], "gold": ["15 min"], "text": "After administration, aspirin is rapidly hydrolyzed in the body with an elimination half-life of approximatly 15 min [11,12]."}, {"generated": ["up to a dilution of 1%"], "gold": [], "text": "Therefore, Samento and Banderol were tested up to a dilution of 1% in the induction assay."}, {"generated": ["t = 0"], "gold": [], "text": "Expression of CYP2J2 mRNA was quantified by RT-PCR and results normalized to \u03b22mg and to t = 0."}, {"generated": ["for 2 weeks"], "gold": [], "text": "Subjects were also asked to abstain from taking prescription and over the counter medications for 2 weeks before and during the study period."}, {"generated": ["12 h", "one week"], "gold": [], "text": "All animals were retained in polypropylene cages: 6 animals were caged (n = 6) per cage with a 12-h light/dark cycle, at 25 \u00b0C in humane conditions with free access to food and water and adapted to the living conditions one week prior to experiment The animals were categorized into four groups (n = 6) and fasted for 12 h before the experiment."}, {"generated": ["12 h", "one week"], "gold": [], "text": "All animals were retained in polypropylene cages: 6 animals were caged (n = 6) per cage with a 12-h light/dark cycle, at 25 \u00b0C in humane conditions with free access to food and water and adapted to the living conditions one week prior to experiment The animals were categorized into four groups (n = 6) and fasted for 12 h before the experiment."}, {"generated": ["for 7 days", "on the 7th day"], "gold": ["for 7 days"], "text": "Group I and II were orally administered with normal saline for 7 days and Group II was orally administered DAS (25 mg/kg) on the 7th day."}, {"generated": ["for 7 days", "on the 7th day"], "gold": ["for 7 days"], "text": "on the 7th day, 2\u2009h after APG 40 mg/kg administration, and Group IV was administered with APG 40 mg/kg for 7 days."}, {"generated": ["2 min"], "gold": [], "text": "In the main test session, subjects performed 5 isokinetic knee extensions of the leg at an angular velocity of 60 degrees/second, and subjects recovered passively for 2 min between sets of measurements [26,27]."}, {"generated": ["after 12 weeks"], "gold": ["12 weeks"], "text": "Resting lactate level was measured at baseline and after 12 weeks, and results are presented in Figure 2."}, {"generated": ["about 20 years ago"], "gold": [], "text": "The first clinically relevant reports of preparations of St. John's wort (SJW), a herbal medicine with anti\u2010depressant effects, interacting with other drugs, altering their bioavailability and efficacy, were published about 20 years ago."}, {"generated": ["seven test drugs", "before"], "gold": [], "text": "This statement was provided even before another comprehensive pharmacokinetic interaction study was published, where no clinically relevant interactions were found for seven test drugs in concomitant application with a low\u2010hyperforin SJW extract (Zahner et al., 2019)."}, {"generated": ["seven test drugs", "before"], "gold": [], "text": "This statement was provided even before another comprehensive pharmacokinetic interaction study was published, where no clinically relevant interactions were found for seven test drugs in concomitant application with a low\u2010hyperforin SJW extract (Zahner et al., 2019)."}, {"generated": ["induce cell cycle arrest at different phases", "platelets", "delayed hypersensitivity", "for 7 days", "less decrease in WBC", "for 12 weeks", "increase caspase 3 and 8 expression and activity", "increase in survival", "increase appetite", "better symptomatic relief", "increase in survival time", "other bone marrow cells", "increase in T cells count (CD4, CD4/CD8)", "increase in efficacy and survival", "greater recovery rate from intestinal damage", "less reduction in WBC (CD3+, CD4+ T cells, NK cells)", "increase in tumor inhibition effect"], "gold": [], "text": "Reduce T cell apoptosis and caspase 3 activity through downregulating Bax expression in T cells [170] Increase in efficacy and survival [20], better symptomatic relief [20] increase in T cells count (CD4, CD4/CD8) [20] Better symptomatic relief [141] and increase appetite [144] Less reduction in WBC (CD3+, CD4+ T cells, NK cells) [141, 144], platelets [144] Pharmacodynamic interactions between medicinal mushrooms and cytotoxic drugs in preclinical studies Increase in tumor inhibition effect [83, 84, 98] and survival time [63] Less decrease in WBC [83, 84, 145], platelets [83] and other bone marrow cells [84] Greater recovery rate from intestinal damage caused by 5-FU [173] Increase in survival [67], cytotoxicity and inhibit metastasis [111] Reduce immunosuppression (reduce the decrease in phagocytic activity, antibody production [111], delayed hypersensitivity [111, 112]) Increase in tumor inhibition and apoptotic rate (dose-related or time-dependent) [98\u2013103], similar effect at lower dose of 5-FU [105] Induce cell cycle arrest at different phases [99, 101], increase caspase 3 and 8 expression and activity [100]."}, {"generated": ["induce cell cycle arrest at different phases", "platelets", "delayed hypersensitivity", "for 7 days", "less decrease in WBC", "for 12 weeks", "increase caspase 3 and 8 expression and activity", "increase in survival", "increase appetite", "better symptomatic relief", "increase in survival time", "other bone marrow cells", "increase in T cells count (CD4, CD4/CD8)", "increase in efficacy and survival", "greater recovery rate from intestinal damage", "less reduction in WBC (CD3+, CD4+ T cells, NK cells)", "increase in tumor inhibition effect"], "gold": [], "text": "Reduce T cell apoptosis and caspase 3 activity through downregulating Bax expression in T cells [170] Increase in efficacy and survival [20], better symptomatic relief [20] increase in T cells count (CD4, CD4/CD8) [20] Better symptomatic relief [141] and increase appetite [144] Less reduction in WBC (CD3+, CD4+ T cells, NK cells) [141, 144], platelets [144] Pharmacodynamic interactions between medicinal mushrooms and cytotoxic drugs in preclinical studies Increase in tumor inhibition effect [83, 84, 98] and survival time [63] Less decrease in WBC [83, 84, 145], platelets [83] and other bone marrow cells [84] Greater recovery rate from intestinal damage caused by 5-FU [173] Increase in survival [67], cytotoxicity and inhibit metastasis [111] Reduce immunosuppression (reduce the decrease in phagocytic activity, antibody production [111], delayed hypersensitivity [111, 112]) Increase in tumor inhibition and apoptotic rate (dose-related or time-dependent) [98\u2013103], similar effect at lower dose of 5-FU [105] Induce cell cycle arrest at different phases [99, 101], increase caspase 3 and 8 expression and activity [100]."}, {"generated": ["induce cell cycle arrest at different phases", "platelets", "delayed hypersensitivity", "for 7 days", "less decrease in WBC", "for 12 weeks", "increase caspase 3 and 8 expression and activity", "increase in survival", "increase appetite", "better symptomatic relief", "increase in survival time", "other bone marrow cells", "increase in T cells count (CD4, CD4/CD8)", "increase in efficacy and survival", "greater recovery rate from intestinal damage", "less reduction in WBC (CD3+, CD4+ T cells, NK cells)", "increase in tumor inhibition effect"], "gold": [], "text": "Reduce T cell apoptosis and caspase 3 activity through downregulating Bax expression in T cells [170] Increase in efficacy and survival [20], better symptomatic relief [20] increase in T cells count (CD4, CD4/CD8) [20] Better symptomatic relief [141] and increase appetite [144] Less reduction in WBC (CD3+, CD4+ T cells, NK cells) [141, 144], platelets [144] Pharmacodynamic interactions between medicinal mushrooms and cytotoxic drugs in preclinical studies Increase in tumor inhibition effect [83, 84, 98] and survival time [63] Less decrease in WBC [83, 84, 145], platelets [83] and other bone marrow cells [84] Greater recovery rate from intestinal damage caused by 5-FU [173] Increase in survival [67], cytotoxicity and inhibit metastasis [111] Reduce immunosuppression (reduce the decrease in phagocytic activity, antibody production [111], delayed hypersensitivity [111, 112]) Increase in tumor inhibition and apoptotic rate (dose-related or time-dependent) [98\u2013103], similar effect at lower dose of 5-FU [105] Induce cell cycle arrest at different phases [99, 101], increase caspase 3 and 8 expression and activity [100]."}, {"generated": ["induce cell cycle arrest at different phases", "platelets", "delayed hypersensitivity", "for 7 days", "less decrease in WBC", "for 12 weeks", "increase caspase 3 and 8 expression and activity", "increase in survival", "increase appetite", "better symptomatic relief", "increase in survival time", "other bone marrow cells", "increase in T cells count (CD4, CD4/CD8)", "increase in efficacy and survival", "greater recovery rate from intestinal damage", "less reduction in WBC (CD3+, CD4+ T cells, NK cells)", "increase in tumor inhibition effect"], "gold": [], "text": "Reduce T cell apoptosis and caspase 3 activity through downregulating Bax expression in T cells [170] Increase in efficacy and survival [20], better symptomatic relief [20] increase in T cells count (CD4, CD4/CD8) [20] Better symptomatic relief [141] and increase appetite [144] Less reduction in WBC (CD3+, CD4+ T cells, NK cells) [141, 144], platelets [144] Pharmacodynamic interactions between medicinal mushrooms and cytotoxic drugs in preclinical studies Increase in tumor inhibition effect [83, 84, 98] and survival time [63] Less decrease in WBC [83, 84, 145], platelets [83] and other bone marrow cells [84] Greater recovery rate from intestinal damage caused by 5-FU [173] Increase in survival [67], cytotoxicity and inhibit metastasis [111] Reduce immunosuppression (reduce the decrease in phagocytic activity, antibody production [111], delayed hypersensitivity [111, 112]) Increase in tumor inhibition and apoptotic rate (dose-related or time-dependent) [98\u2013103], similar effect at lower dose of 5-FU [105] Induce cell cycle arrest at different phases [99, 101], increase caspase 3 and 8 expression and activity [100]."}, {"generated": ["induce cell cycle arrest at different phases", "platelets", "delayed hypersensitivity", "for 7 days", "less decrease in WBC", "for 12 weeks", "increase caspase 3 and 8 expression and activity", "increase in survival", "increase appetite", "better symptomatic relief", "increase in survival time", "other bone marrow cells", "increase in T cells count (CD4, CD4/CD8)", "increase in efficacy and survival", "greater recovery rate from intestinal damage", "less reduction in WBC (CD3+, CD4+ T cells, NK cells)", "increase in tumor inhibition effect"], "gold": [], "text": "Reduce T cell apoptosis and caspase 3 activity through downregulating Bax expression in T cells [170] Increase in efficacy and survival [20], better symptomatic relief [20] increase in T cells count (CD4, CD4/CD8) [20] Better symptomatic relief [141] and increase appetite [144] Less reduction in WBC (CD3+, CD4+ T cells, NK cells) [141, 144], platelets [144] Pharmacodynamic interactions between medicinal mushrooms and cytotoxic drugs in preclinical studies Increase in tumor inhibition effect [83, 84, 98] and survival time [63] Less decrease in WBC [83, 84, 145], platelets [83] and other bone marrow cells [84] Greater recovery rate from intestinal damage caused by 5-FU [173] Increase in survival [67], cytotoxicity and inhibit metastasis [111] Reduce immunosuppression (reduce the decrease in phagocytic activity, antibody production [111], delayed hypersensitivity [111, 112]) Increase in tumor inhibition and apoptotic rate (dose-related or time-dependent) [98\u2013103], similar effect at lower dose of 5-FU [105] Induce cell cycle arrest at different phases [99, 101], increase caspase 3 and 8 expression and activity [100]."}, {"generated": ["induce cell cycle arrest at different phases", "platelets", "delayed hypersensitivity", "for 7 days", "less decrease in WBC", "for 12 weeks", "increase caspase 3 and 8 expression and activity", "increase in survival", "increase appetite", "better symptomatic relief", "increase in survival time", "other bone marrow cells", "increase in T cells count (CD4, CD4/CD8)", "increase in efficacy and survival", "greater recovery rate from intestinal damage", "less reduction in WBC (CD3+, CD4+ T cells, NK cells)", "increase in tumor inhibition effect"], "gold": [], "text": "Reduce T cell apoptosis and caspase 3 activity through downregulating Bax expression in T cells [170] Increase in efficacy and survival [20], better symptomatic relief [20] increase in T cells count (CD4, CD4/CD8) [20] Better symptomatic relief [141] and increase appetite [144] Less reduction in WBC (CD3+, CD4+ T cells, NK cells) [141, 144], platelets [144] Pharmacodynamic interactions between medicinal mushrooms and cytotoxic drugs in preclinical studies Increase in tumor inhibition effect [83, 84, 98] and survival time [63] Less decrease in WBC [83, 84, 145], platelets [83] and other bone marrow cells [84] Greater recovery rate from intestinal damage caused by 5-FU [173] Increase in survival [67], cytotoxicity and inhibit metastasis [111] Reduce immunosuppression (reduce the decrease in phagocytic activity, antibody production [111], delayed hypersensitivity [111, 112]) Increase in tumor inhibition and apoptotic rate (dose-related or time-dependent) [98\u2013103], similar effect at lower dose of 5-FU [105] Induce cell cycle arrest at different phases [99, 101], increase caspase 3 and 8 expression and activity [100]."}, {"generated": ["induce cell cycle arrest at different phases", "platelets", "delayed hypersensitivity", "for 7 days", "less decrease in WBC", "for 12 weeks", "increase caspase 3 and 8 expression and activity", "increase in survival", "increase appetite", "better symptomatic relief", "increase in survival time", "other bone marrow cells", "increase in T cells count (CD4, CD4/CD8)", "increase in efficacy and survival", "greater recovery rate from intestinal damage", "less reduction in WBC (CD3+, CD4+ T cells, NK cells)", "increase in tumor inhibition effect"], "gold": [], "text": "Reduce T cell apoptosis and caspase 3 activity through downregulating Bax expression in T cells [170] Increase in efficacy and survival [20], better symptomatic relief [20] increase in T cells count (CD4, CD4/CD8) [20] Better symptomatic relief [141] and increase appetite [144] Less reduction in WBC (CD3+, CD4+ T cells, NK cells) [141, 144], platelets [144] Pharmacodynamic interactions between medicinal mushrooms and cytotoxic drugs in preclinical studies Increase in tumor inhibition effect [83, 84, 98] and survival time [63] Less decrease in WBC [83, 84, 145], platelets [83] and other bone marrow cells [84] Greater recovery rate from intestinal damage caused by 5-FU [173] Increase in survival [67], cytotoxicity and inhibit metastasis [111] Reduce immunosuppression (reduce the decrease in phagocytic activity, antibody production [111], delayed hypersensitivity [111, 112]) Increase in tumor inhibition and apoptotic rate (dose-related or time-dependent) [98\u2013103], similar effect at lower dose of 5-FU [105] Induce cell cycle arrest at different phases [99, 101], increase caspase 3 and 8 expression and activity [100]."}, {"generated": ["induce cell cycle arrest at different phases", "platelets", "delayed hypersensitivity", "for 7 days", "less decrease in WBC", "for 12 weeks", "increase caspase 3 and 8 expression and activity", "increase in survival", "increase appetite", "better symptomatic relief", "increase in survival time", "other bone marrow cells", "increase in T cells count (CD4, CD4/CD8)", "increase in efficacy and survival", "greater recovery rate from intestinal damage", "less reduction in WBC (CD3+, CD4+ T cells, NK cells)", "increase in tumor inhibition effect"], "gold": [], "text": "Reduce T cell apoptosis and caspase 3 activity through downregulating Bax expression in T cells [170] Increase in efficacy and survival [20], better symptomatic relief [20] increase in T cells count (CD4, CD4/CD8) [20] Better symptomatic relief [141] and increase appetite [144] Less reduction in WBC (CD3+, CD4+ T cells, NK cells) [141, 144], platelets [144] Pharmacodynamic interactions between medicinal mushrooms and cytotoxic drugs in preclinical studies Increase in tumor inhibition effect [83, 84, 98] and survival time [63] Less decrease in WBC [83, 84, 145], platelets [83] and other bone marrow cells [84] Greater recovery rate from intestinal damage caused by 5-FU [173] Increase in survival [67], cytotoxicity and inhibit metastasis [111] Reduce immunosuppression (reduce the decrease in phagocytic activity, antibody production [111], delayed hypersensitivity [111, 112]) Increase in tumor inhibition and apoptotic rate (dose-related or time-dependent) [98\u2013103], similar effect at lower dose of 5-FU [105] Induce cell cycle arrest at different phases [99, 101], increase caspase 3 and 8 expression and activity [100]."}, {"generated": ["induce cell cycle arrest at different phases", "platelets", "delayed hypersensitivity", "for 7 days", "less decrease in WBC", "for 12 weeks", "increase caspase 3 and 8 expression and activity", "increase in survival", "increase appetite", "better symptomatic relief", "increase in survival time", "other bone marrow cells", "increase in T cells count (CD4, CD4/CD8)", "increase in efficacy and survival", "greater recovery rate from intestinal damage", "less reduction in WBC (CD3+, CD4+ T cells, NK cells)", "increase in tumor inhibition effect"], "gold": [], "text": "Reduce T cell apoptosis and caspase 3 activity through downregulating Bax expression in T cells [170] Increase in efficacy and survival [20], better symptomatic relief [20] increase in T cells count (CD4, CD4/CD8) [20] Better symptomatic relief [141] and increase appetite [144] Less reduction in WBC (CD3+, CD4+ T cells, NK cells) [141, 144], platelets [144] Pharmacodynamic interactions between medicinal mushrooms and cytotoxic drugs in preclinical studies Increase in tumor inhibition effect [83, 84, 98] and survival time [63] Less decrease in WBC [83, 84, 145], platelets [83] and other bone marrow cells [84] Greater recovery rate from intestinal damage caused by 5-FU [173] Increase in survival [67], cytotoxicity and inhibit metastasis [111] Reduce immunosuppression (reduce the decrease in phagocytic activity, antibody production [111], delayed hypersensitivity [111, 112]) Increase in tumor inhibition and apoptotic rate (dose-related or time-dependent) [98\u2013103], similar effect at lower dose of 5-FU [105] Induce cell cycle arrest at different phases [99, 101], increase caspase 3 and 8 expression and activity [100]."}, {"generated": ["induce cell cycle arrest at different phases", "platelets", "delayed hypersensitivity", "for 7 days", "less decrease in WBC", "for 12 weeks", "increase caspase 3 and 8 expression and activity", "increase in survival", "increase appetite", "better symptomatic relief", "increase in survival time", "other bone marrow cells", "increase in T cells count (CD4, CD4/CD8)", "increase in efficacy and survival", "greater recovery rate from intestinal damage", "less reduction in WBC (CD3+, CD4+ T cells, NK cells)", "increase in tumor inhibition effect"], "gold": [], "text": "Reduce T cell apoptosis and caspase 3 activity through downregulating Bax expression in T cells [170] Increase in efficacy and survival [20], better symptomatic relief [20] increase in T cells count (CD4, CD4/CD8) [20] Better symptomatic relief [141] and increase appetite [144] Less reduction in WBC (CD3+, CD4+ T cells, NK cells) [141, 144], platelets [144] Pharmacodynamic interactions between medicinal mushrooms and cytotoxic drugs in preclinical studies Increase in tumor inhibition effect [83, 84, 98] and survival time [63] Less decrease in WBC [83, 84, 145], platelets [83] and other bone marrow cells [84] Greater recovery rate from intestinal damage caused by 5-FU [173] Increase in survival [67], cytotoxicity and inhibit metastasis [111] Reduce immunosuppression (reduce the decrease in phagocytic activity, antibody production [111], delayed hypersensitivity [111, 112]) Increase in tumor inhibition and apoptotic rate (dose-related or time-dependent) [98\u2013103], similar effect at lower dose of 5-FU [105] Induce cell cycle arrest at different phases [99, 101], increase caspase 3 and 8 expression and activity [100]."}, {"generated": ["induce cell cycle arrest at different phases", "platelets", "delayed hypersensitivity", "for 7 days", "less decrease in WBC", "for 12 weeks", "increase caspase 3 and 8 expression and activity", "increase in survival", "increase appetite", "better symptomatic relief", "increase in survival time", "other bone marrow cells", "increase in T cells count (CD4, CD4/CD8)", "increase in efficacy and survival", "greater recovery rate from intestinal damage", "less reduction in WBC (CD3+, CD4+ T cells, NK cells)", "increase in tumor inhibition effect"], "gold": [], "text": "Reduce T cell apoptosis and caspase 3 activity through downregulating Bax expression in T cells [170] Increase in efficacy and survival [20], better symptomatic relief [20] increase in T cells count (CD4, CD4/CD8) [20] Better symptomatic relief [141] and increase appetite [144] Less reduction in WBC (CD3+, CD4+ T cells, NK cells) [141, 144], platelets [144] Pharmacodynamic interactions between medicinal mushrooms and cytotoxic drugs in preclinical studies Increase in tumor inhibition effect [83, 84, 98] and survival time [63] Less decrease in WBC [83, 84, 145], platelets [83] and other bone marrow cells [84] Greater recovery rate from intestinal damage caused by 5-FU [173] Increase in survival [67], cytotoxicity and inhibit metastasis [111] Reduce immunosuppression (reduce the decrease in phagocytic activity, antibody production [111], delayed hypersensitivity [111, 112]) Increase in tumor inhibition and apoptotic rate (dose-related or time-dependent) [98\u2013103], similar effect at lower dose of 5-FU [105] Induce cell cycle arrest at different phases [99, 101], increase caspase 3 and 8 expression and activity [100]."}, {"generated": ["induce cell cycle arrest at different phases", "platelets", "delayed hypersensitivity", "for 7 days", "less decrease in WBC", "for 12 weeks", "increase caspase 3 and 8 expression and activity", "increase in survival", "increase appetite", "better symptomatic relief", "increase in survival time", "other bone marrow cells", "increase in T cells count (CD4, CD4/CD8)", "increase in efficacy and survival", "greater recovery rate from intestinal damage", "less reduction in WBC (CD3+, CD4+ T cells, NK cells)", "increase in tumor inhibition effect"], "gold": [], "text": "Reduce T cell apoptosis and caspase 3 activity through downregulating Bax expression in T cells [170] Increase in efficacy and survival [20], better symptomatic relief [20] increase in T cells count (CD4, CD4/CD8) [20] Better symptomatic relief [141] and increase appetite [144] Less reduction in WBC (CD3+, CD4+ T cells, NK cells) [141, 144], platelets [144] Pharmacodynamic interactions between medicinal mushrooms and cytotoxic drugs in preclinical studies Increase in tumor inhibition effect [83, 84, 98] and survival time [63] Less decrease in WBC [83, 84, 145], platelets [83] and other bone marrow cells [84] Greater recovery rate from intestinal damage caused by 5-FU [173] Increase in survival [67], cytotoxicity and inhibit metastasis [111] Reduce immunosuppression (reduce the decrease in phagocytic activity, antibody production [111], delayed hypersensitivity [111, 112]) Increase in tumor inhibition and apoptotic rate (dose-related or time-dependent) [98\u2013103], similar effect at lower dose of 5-FU [105] Induce cell cycle arrest at different phases [99, 101], increase caspase 3 and 8 expression and activity [100]."}, {"generated": ["induce cell cycle arrest at different phases", "platelets", "delayed hypersensitivity", "for 7 days", "less decrease in WBC", "for 12 weeks", "increase caspase 3 and 8 expression and activity", "increase in survival", "increase appetite", "better symptomatic relief", "increase in survival time", "other bone marrow cells", "increase in T cells count (CD4, CD4/CD8)", "increase in efficacy and survival", "greater recovery rate from intestinal damage", "less reduction in WBC (CD3+, CD4+ T cells, NK cells)", "increase in tumor inhibition effect"], "gold": [], "text": "Reduce T cell apoptosis and caspase 3 activity through downregulating Bax expression in T cells [170] Increase in efficacy and survival [20], better symptomatic relief [20] increase in T cells count (CD4, CD4/CD8) [20] Better symptomatic relief [141] and increase appetite [144] Less reduction in WBC (CD3+, CD4+ T cells, NK cells) [141, 144], platelets [144] Pharmacodynamic interactions between medicinal mushrooms and cytotoxic drugs in preclinical studies Increase in tumor inhibition effect [83, 84, 98] and survival time [63] Less decrease in WBC [83, 84, 145], platelets [83] and other bone marrow cells [84] Greater recovery rate from intestinal damage caused by 5-FU [173] Increase in survival [67], cytotoxicity and inhibit metastasis [111] Reduce immunosuppression (reduce the decrease in phagocytic activity, antibody production [111], delayed hypersensitivity [111, 112]) Increase in tumor inhibition and apoptotic rate (dose-related or time-dependent) [98\u2013103], similar effect at lower dose of 5-FU [105] Induce cell cycle arrest at different phases [99, 101], increase caspase 3 and 8 expression and activity [100]."}, {"generated": ["induce cell cycle arrest at different phases", "platelets", "delayed hypersensitivity", "for 7 days", "less decrease in WBC", "for 12 weeks", "increase caspase 3 and 8 expression and activity", "increase in survival", "increase appetite", "better symptomatic relief", "increase in survival time", "other bone marrow cells", "increase in T cells count (CD4, CD4/CD8)", "increase in efficacy and survival", "greater recovery rate from intestinal damage", "less reduction in WBC (CD3+, CD4+ T cells, NK cells)", "increase in tumor inhibition effect"], "gold": [], "text": "Reduce T cell apoptosis and caspase 3 activity through downregulating Bax expression in T cells [170] Increase in efficacy and survival [20], better symptomatic relief [20] increase in T cells count (CD4, CD4/CD8) [20] Better symptomatic relief [141] and increase appetite [144] Less reduction in WBC (CD3+, CD4+ T cells, NK cells) [141, 144], platelets [144] Pharmacodynamic interactions between medicinal mushrooms and cytotoxic drugs in preclinical studies Increase in tumor inhibition effect [83, 84, 98] and survival time [63] Less decrease in WBC [83, 84, 145], platelets [83] and other bone marrow cells [84] Greater recovery rate from intestinal damage caused by 5-FU [173] Increase in survival [67], cytotoxicity and inhibit metastasis [111] Reduce immunosuppression (reduce the decrease in phagocytic activity, antibody production [111], delayed hypersensitivity [111, 112]) Increase in tumor inhibition and apoptotic rate (dose-related or time-dependent) [98\u2013103], similar effect at lower dose of 5-FU [105] Induce cell cycle arrest at different phases [99, 101], increase caspase 3 and 8 expression and activity [100]."}, {"generated": ["induce cell cycle arrest at different phases", "platelets", "delayed hypersensitivity", "for 7 days", "less decrease in WBC", "for 12 weeks", "increase caspase 3 and 8 expression and activity", "increase in survival", "increase appetite", "better symptomatic relief", "increase in survival time", "other bone marrow cells", "increase in T cells count (CD4, CD4/CD8)", "increase in efficacy and survival", "greater recovery rate from intestinal damage", "less reduction in WBC (CD3+, CD4+ T cells, NK cells)", "increase in tumor inhibition effect"], "gold": [], "text": "Reduce T cell apoptosis and caspase 3 activity through downregulating Bax expression in T cells [170] Increase in efficacy and survival [20], better symptomatic relief [20] increase in T cells count (CD4, CD4/CD8) [20] Better symptomatic relief [141] and increase appetite [144] Less reduction in WBC (CD3+, CD4+ T cells, NK cells) [141, 144], platelets [144] Pharmacodynamic interactions between medicinal mushrooms and cytotoxic drugs in preclinical studies Increase in tumor inhibition effect [83, 84, 98] and survival time [63] Less decrease in WBC [83, 84, 145], platelets [83] and other bone marrow cells [84] Greater recovery rate from intestinal damage caused by 5-FU [173] Increase in survival [67], cytotoxicity and inhibit metastasis [111] Reduce immunosuppression (reduce the decrease in phagocytic activity, antibody production [111], delayed hypersensitivity [111, 112]) Increase in tumor inhibition and apoptotic rate (dose-related or time-dependent) [98\u2013103], similar effect at lower dose of 5-FU [105] Induce cell cycle arrest at different phases [99, 101], increase caspase 3 and 8 expression and activity [100]."}, {"generated": ["induce cell cycle arrest at different phases", "platelets", "delayed hypersensitivity", "for 7 days", "less decrease in WBC", "for 12 weeks", "increase caspase 3 and 8 expression and activity", "increase in survival", "increase appetite", "better symptomatic relief", "increase in survival time", "other bone marrow cells", "increase in T cells count (CD4, CD4/CD8)", "increase in efficacy and survival", "greater recovery rate from intestinal damage", "less reduction in WBC (CD3+, CD4+ T cells, NK cells)", "increase in tumor inhibition effect"], "gold": [], "text": "Reduce T cell apoptosis and caspase 3 activity through downregulating Bax expression in T cells [170] Increase in efficacy and survival [20], better symptomatic relief [20] increase in T cells count (CD4, CD4/CD8) [20] Better symptomatic relief [141] and increase appetite [144] Less reduction in WBC (CD3+, CD4+ T cells, NK cells) [141, 144], platelets [144] Pharmacodynamic interactions between medicinal mushrooms and cytotoxic drugs in preclinical studies Increase in tumor inhibition effect [83, 84, 98] and survival time [63] Less decrease in WBC [83, 84, 145], platelets [83] and other bone marrow cells [84] Greater recovery rate from intestinal damage caused by 5-FU [173] Increase in survival [67], cytotoxicity and inhibit metastasis [111] Reduce immunosuppression (reduce the decrease in phagocytic activity, antibody production [111], delayed hypersensitivity [111, 112]) Increase in tumor inhibition and apoptotic rate (dose-related or time-dependent) [98\u2013103], similar effect at lower dose of 5-FU [105] Induce cell cycle arrest at different phases [99, 101], increase caspase 3 and 8 expression and activity [100]."}, {"generated": ["induce cell cycle arrest at different phases", "platelets", "delayed hypersensitivity", "for 7 days", "less decrease in WBC", "for 12 weeks", "increase caspase 3 and 8 expression and activity", "increase in survival", "increase appetite", "better symptomatic relief", "increase in survival time", "other bone marrow cells", "increase in T cells count (CD4, CD4/CD8)", "increase in efficacy and survival", "greater recovery rate from intestinal damage", "less reduction in WBC (CD3+, CD4+ T cells, NK cells)", "increase in tumor inhibition effect"], "gold": [], "text": "Reduce T cell apoptosis and caspase 3 activity through downregulating Bax expression in T cells [170] Increase in efficacy and survival [20], better symptomatic relief [20] increase in T cells count (CD4, CD4/CD8) [20] Better symptomatic relief [141] and increase appetite [144] Less reduction in WBC (CD3+, CD4+ T cells, NK cells) [141, 144], platelets [144] Pharmacodynamic interactions between medicinal mushrooms and cytotoxic drugs in preclinical studies Increase in tumor inhibition effect [83, 84, 98] and survival time [63] Less decrease in WBC [83, 84, 145], platelets [83] and other bone marrow cells [84] Greater recovery rate from intestinal damage caused by 5-FU [173] Increase in survival [67], cytotoxicity and inhibit metastasis [111] Reduce immunosuppression (reduce the decrease in phagocytic activity, antibody production [111], delayed hypersensitivity [111, 112]) Increase in tumor inhibition and apoptotic rate (dose-related or time-dependent) [98\u2013103], similar effect at lower dose of 5-FU [105] Induce cell cycle arrest at different phases [99, 101], increase caspase 3 and 8 expression and activity [100]."}, {"generated": ["for 12 weeks"], "gold": [], "text": "a."}, {"generated": ["concentration-dependent inhibition of proliferation"], "gold": [], "text": "Significances are given relative to the VAEM untreated values (*p\u00a0<\u20090.05, **p\u00a0<\u20090.01, ***p\u00a0<\u20090.001) VAEM, as well as endoxifen, showed a concentration-dependent inhibition of proliferation (Fig."}, {"generated": ["long-term"], "gold": [], "text": "The metabolic activity of CYP2D6 was suggested to be associated with the long-term outcomes in breast cancer, although the studies are inconsistent [35]."}, {"generated": ["30 min", "30 seconds"], "gold": [], "text": "For derivatization of plasma captopril, a plasma sample (180\u2009\u00b5L) was first mixed with 20\u2009\u00b5L of 520\u2009ppm 2-4-dibromoacetophenone stock solution and 20\u2009\u00b5L of 5% ammonia solution, vortexed for 30 seconds, and incubated at room temperature for 30\u2009min."}, {"generated": ["30 min", "30 seconds"], "gold": [], "text": "For derivatization of plasma captopril, a plasma sample (180\u2009\u00b5L) was first mixed with 20\u2009\u00b5L of 520\u2009ppm 2-4-dibromoacetophenone stock solution and 20\u2009\u00b5L of 5% ammonia solution, vortexed for 30 seconds, and incubated at room temperature for 30\u2009min."}, {"generated": ["1.0 mL"], "gold": [], "text": "The loss of body fluid was compensated by administrating 1.0\u2009mL saline solution (p.o.)"}, {"generated": ["after seven days"], "gold": [], "text": "After seven days, the extract was filtered and the filtrate was stored in refrigerator until next processing."}, {"generated": ["for 12 weeks"], "gold": [], "text": "3a and b)."}, {"generated": ["significantly"], "gold": [], "text": "Treatment with EJE and EJE\u202f+\u202fSITA significantly (p\u202f<\u202f0.001) reduced the elevated levels of BUN (Fig."}, {"generated": ["4\u20135 h", "0\u20131 h", "3\u20134 h", "6\u20137 h", "1\u20132 h", "5\u20136 h", "2\u20133 h"], "gold": [], "text": "The bile was collected during 0\u20131\u00a0h, 1\u20132\u00a0h, 2\u20133\u00a0h, 3\u20134\u00a0h, 4\u20135\u00a0h, 5\u20136\u00a0h and 6\u20137\u00a0h after dosing."}, {"generated": ["4\u20135 h", "0\u20131 h", "3\u20134 h", "6\u20137 h", "1\u20132 h", "5\u20136 h", "2\u20133 h"], "gold": [], "text": "The bile was collected during 0\u20131\u00a0h, 1\u20132\u00a0h, 2\u20133\u00a0h, 3\u20134\u00a0h, 4\u20135\u00a0h, 5\u20136\u00a0h and 6\u20137\u00a0h after dosing."}, {"generated": ["4\u20135 h", "0\u20131 h", "3\u20134 h", "6\u20137 h", "1\u20132 h", "5\u20136 h", "2\u20133 h"], "gold": [], "text": "The bile was collected during 0\u20131\u00a0h, 1\u20132\u00a0h, 2\u20133\u00a0h, 3\u20134\u00a0h, 4\u20135\u00a0h, 5\u20136\u00a0h and 6\u20137\u00a0h after dosing."}, {"generated": ["4\u20135 h", "0\u20131 h", "3\u20134 h", "6\u20137 h", "1\u20132 h", "5\u20136 h", "2\u20133 h"], "gold": [], "text": "The bile was collected during 0\u20131\u00a0h, 1\u20132\u00a0h, 2\u20133\u00a0h, 3\u20134\u00a0h, 4\u20135\u00a0h, 5\u20136\u00a0h and 6\u20137\u00a0h after dosing."}, {"generated": ["4\u20135 h", "0\u20131 h", "3\u20134 h", "6\u20137 h", "1\u20132 h", "5\u20136 h", "2\u20133 h"], "gold": [], "text": "The bile was collected during 0\u20131\u00a0h, 1\u20132\u00a0h, 2\u20133\u00a0h, 3\u20134\u00a0h, 4\u20135\u00a0h, 5\u20136\u00a0h and 6\u20137\u00a0h after dosing."}, {"generated": ["4\u20135 h", "0\u20131 h", "3\u20134 h", "6\u20137 h", "1\u20132 h", "5\u20136 h", "2\u20133 h"], "gold": [], "text": "The bile was collected during 0\u20131\u00a0h, 1\u20132\u00a0h, 2\u20133\u00a0h, 3\u20134\u00a0h, 4\u20135\u00a0h, 5\u20136\u00a0h and 6\u20137\u00a0h after dosing."}, {"generated": ["4\u20135 h", "0\u20131 h", "3\u20134 h", "6\u20137 h", "1\u20132 h", "5\u20136 h", "2\u20133 h"], "gold": [], "text": "The bile was collected during 0\u20131\u00a0h, 1\u20132\u00a0h, 2\u20133\u00a0h, 3\u20134\u00a0h, 4\u20135\u00a0h, 5\u20136\u00a0h and 6\u20137\u00a0h after dosing."}, {"generated": ["0\u20136 h", "6\u201318 h", "18\u201328 h"], "gold": [], "text": "Urine and feces were collected 0\u20136\u00a0h, 6\u201318\u00a0h and 18\u201328\u00a0h after administration."}, {"generated": ["0\u20136 h", "6\u201318 h", "18\u201328 h"], "gold": [], "text": "Urine and feces were collected 0\u20136\u00a0h, 6\u201318\u00a0h and 18\u201328\u00a0h after administration."}, {"generated": ["0\u20136 h", "6\u201318 h", "18\u201328 h"], "gold": [], "text": "Urine and feces were collected 0\u20136\u00a0h, 6\u201318\u00a0h and 18\u201328\u00a0h after administration."}, {"generated": ["for 12 weeks"], "gold": [], "text": "1)."}, {"generated": ["monthly", "on a maintenance daily dose"], "gold": [], "text": "The patient was compliant regarding the attendance of appointments and in taking the medication, and maintained a therapeutic INR (1.7\u20132.5) on a maintenance daily dose of 1.875 mg warfarin with monthly INR monitoring."}, {"generated": ["monthly", "on a maintenance daily dose"], "gold": [], "text": "The patient was compliant regarding the attendance of appointments and in taking the medication, and maintained a therapeutic INR (1.7\u20132.5) on a maintenance daily dose of 1.875 mg warfarin with monthly INR monitoring."}, {"generated": ["occasionally"], "gold": [], "text": "[7] previously showed that administration of 375 ml wine did not result in thrombin times (TTs) outside the therapeutic range, which suggested that a moderate intake of alcohol occasionally may be acceptable during anticoagulant therapy."}, {"generated": ["15 days"], "gold": ["15 day"], "text": "One brief 15 day study reported a significant increase in total cholesterol among hypertensive patients administered HS [18]."}, {"generated": ["for 12 weeks"], "gold": [], "text": "2.1.2."}, {"generated": ["by placing the tubes on a cooling block"], "gold": [], "text": "The reaction was initiated by the addition of NADPH and terminated by placing the tubes on a cooling block (Selleckchem, Houston, TX, USA)."}, {"generated": ["next 12 min", "next 13 min", "15 min", "next 10 min", "first 5 min", "5 min"], "gold": [], "text": "The linear gradient elution was carried out as follows with a total running time of 90\u00a0min: solvent A was kept at 5\u00a0% for the first 5\u00a0min, and then increased to 10, 17, 35 and 90\u00a0% in the next 13, 12, 10 and 30\u00a0min, respectively, then returned to 5\u00a0% in 5\u00a0min and equilibrated for 15\u00a0min before the next injection."}, {"generated": ["next 12 min", "next 13 min", "15 min", "next 10 min", "first 5 min", "5 min"], "gold": [], "text": "The linear gradient elution was carried out as follows with a total running time of 90\u00a0min: solvent A was kept at 5\u00a0% for the first 5\u00a0min, and then increased to 10, 17, 35 and 90\u00a0% in the next 13, 12, 10 and 30\u00a0min, respectively, then returned to 5\u00a0% in 5\u00a0min and equilibrated for 15\u00a0min before the next injection."}, {"generated": ["next 12 min", "next 13 min", "15 min", "next 10 min", "first 5 min", "5 min"], "gold": [], "text": "The linear gradient elution was carried out as follows with a total running time of 90\u00a0min: solvent A was kept at 5\u00a0% for the first 5\u00a0min, and then increased to 10, 17, 35 and 90\u00a0% in the next 13, 12, 10 and 30\u00a0min, respectively, then returned to 5\u00a0% in 5\u00a0min and equilibrated for 15\u00a0min before the next injection."}, {"generated": ["next 12 min", "next 13 min", "15 min", "next 10 min", "first 5 min", "5 min"], "gold": [], "text": "The linear gradient elution was carried out as follows with a total running time of 90\u00a0min: solvent A was kept at 5\u00a0% for the first 5\u00a0min, and then increased to 10, 17, 35 and 90\u00a0% in the next 13, 12, 10 and 30\u00a0min, respectively, then returned to 5\u00a0% in 5\u00a0min and equilibrated for 15\u00a0min before the next injection."}, {"generated": ["next 12 min", "next 13 min", "15 min", "next 10 min", "first 5 min", "5 min"], "gold": [], "text": "The linear gradient elution was carried out as follows with a total running time of 90\u00a0min: solvent A was kept at 5\u00a0% for the first 5\u00a0min, and then increased to 10, 17, 35 and 90\u00a0% in the next 13, 12, 10 and 30\u00a0min, respectively, then returned to 5\u00a0% in 5\u00a0min and equilibrated for 15\u00a0min before the next injection."}, {"generated": ["next 12 min", "next 13 min", "15 min", "next 10 min", "first 5 min", "5 min"], "gold": [], "text": "The linear gradient elution was carried out as follows with a total running time of 90\u00a0min: solvent A was kept at 5\u00a0% for the first 5\u00a0min, and then increased to 10, 17, 35 and 90\u00a0% in the next 13, 12, 10 and 30\u00a0min, respectively, then returned to 5\u00a0% in 5\u00a0min and equilibrated for 15\u00a0min before the next injection."}, {"generated": ["37 months", "113 months"], "gold": [], "text": "The 48 (80%) women who had received adjuvant chemotherapy were a mean of 37\u2009months (range 4\u2013113) from completion of chemotherapy."}, {"generated": ["37 months", "113 months"], "gold": [], "text": "The 48 (80%) women who had received adjuvant chemotherapy were a mean of 37\u2009months (range 4\u2013113) from completion of chemotherapy."}, {"generated": ["for 7 days", "for 12 weeks", "in vitro", "for 6 days", "in vitro inhibited"], "gold": [], "text": "Increasing use of medicinal herbs as nutritional supplements and traditional medicines for the treatment of diabetes, hypertension, hyperlipidemia, and malaria fever with conventional drugs poses possibilities of herb\u2013drug interactions ( In vitro inhibition of eight major   Mangifera indica moderately inhibited  Potential for clinically important     Funding information  This research did not receive any specific grant from funding agencies in the public, commercial, or not\u2010for\u2010profit sectors Management of chronic diseases is burdensome to patients (Eton et\u00a0al., 2013; \u00d8rtenblad, Meillier, & J\u00f8nsson, 2017) who tend to seek alternative remedies to conventional medications that may supposedly provide cure or offer safe use (Yarney et\u00a0al., 2013; Joeliantina, Agil, Qomaruddin, Jonosewojo, & Kusnanto, 2016) This self\u2010medication practice is common among chronically ill patients or patients with terminal diseases (Bodenheimer, Lorig, Holman, & Grumbach, 2002; Hasan, Ahmed, Bukhari, & Loon, 2009), and the major culprit in this group of patients are dietary supplements and herbal medicines (Gardiner, Graham, Legedza, Eisenberg, & Phillips, 2006; Gardiner, Phillips, & Shaughnessy, 2008)."}, {"generated": ["for 7 days", "for 12 weeks", "in vitro", "for 6 days", "in vitro inhibited"], "gold": [], "text": "Increasing use of medicinal herbs as nutritional supplements and traditional medicines for the treatment of diabetes, hypertension, hyperlipidemia, and malaria fever with conventional drugs poses possibilities of herb\u2013drug interactions ( In vitro inhibition of eight major   Mangifera indica moderately inhibited  Potential for clinically important     Funding information  This research did not receive any specific grant from funding agencies in the public, commercial, or not\u2010for\u2010profit sectors Management of chronic diseases is burdensome to patients (Eton et\u00a0al., 2013; \u00d8rtenblad, Meillier, & J\u00f8nsson, 2017) who tend to seek alternative remedies to conventional medications that may supposedly provide cure or offer safe use (Yarney et\u00a0al., 2013; Joeliantina, Agil, Qomaruddin, Jonosewojo, & Kusnanto, 2016) This self\u2010medication practice is common among chronically ill patients or patients with terminal diseases (Bodenheimer, Lorig, Holman, & Grumbach, 2002; Hasan, Ahmed, Bukhari, & Loon, 2009), and the major culprit in this group of patients are dietary supplements and herbal medicines (Gardiner, Graham, Legedza, Eisenberg, & Phillips, 2006; Gardiner, Phillips, & Shaughnessy, 2008)."}, {"generated": ["for 7 days", "for 12 weeks", "in vitro", "for 6 days", "in vitro inhibited"], "gold": [], "text": "Increasing use of medicinal herbs as nutritional supplements and traditional medicines for the treatment of diabetes, hypertension, hyperlipidemia, and malaria fever with conventional drugs poses possibilities of herb\u2013drug interactions ( In vitro inhibition of eight major   Mangifera indica moderately inhibited  Potential for clinically important     Funding information  This research did not receive any specific grant from funding agencies in the public, commercial, or not\u2010for\u2010profit sectors Management of chronic diseases is burdensome to patients (Eton et\u00a0al., 2013; \u00d8rtenblad, Meillier, & J\u00f8nsson, 2017) who tend to seek alternative remedies to conventional medications that may supposedly provide cure or offer safe use (Yarney et\u00a0al., 2013; Joeliantina, Agil, Qomaruddin, Jonosewojo, & Kusnanto, 2016) This self\u2010medication practice is common among chronically ill patients or patients with terminal diseases (Bodenheimer, Lorig, Holman, & Grumbach, 2002; Hasan, Ahmed, Bukhari, & Loon, 2009), and the major culprit in this group of patients are dietary supplements and herbal medicines (Gardiner, Graham, Legedza, Eisenberg, & Phillips, 2006; Gardiner, Phillips, & Shaughnessy, 2008)."}, {"generated": ["for 7 days", "for 12 weeks", "in vitro", "for 6 days", "in vitro inhibited"], "gold": [], "text": "Increasing use of medicinal herbs as nutritional supplements and traditional medicines for the treatment of diabetes, hypertension, hyperlipidemia, and malaria fever with conventional drugs poses possibilities of herb\u2013drug interactions ( In vitro inhibition of eight major   Mangifera indica moderately inhibited  Potential for clinically important     Funding information  This research did not receive any specific grant from funding agencies in the public, commercial, or not\u2010for\u2010profit sectors Management of chronic diseases is burdensome to patients (Eton et\u00a0al., 2013; \u00d8rtenblad, Meillier, & J\u00f8nsson, 2017) who tend to seek alternative remedies to conventional medications that may supposedly provide cure or offer safe use (Yarney et\u00a0al., 2013; Joeliantina, Agil, Qomaruddin, Jonosewojo, & Kusnanto, 2016) This self\u2010medication practice is common among chronically ill patients or patients with terminal diseases (Bodenheimer, Lorig, Holman, & Grumbach, 2002; Hasan, Ahmed, Bukhari, & Loon, 2009), and the major culprit in this group of patients are dietary supplements and herbal medicines (Gardiner, Graham, Legedza, Eisenberg, & Phillips, 2006; Gardiner, Phillips, & Shaughnessy, 2008)."}, {"generated": ["for 7 days", "for 12 weeks", "in vitro", "for 6 days", "in vitro inhibited"], "gold": [], "text": "Increasing use of medicinal herbs as nutritional supplements and traditional medicines for the treatment of diabetes, hypertension, hyperlipidemia, and malaria fever with conventional drugs poses possibilities of herb\u2013drug interactions ( In vitro inhibition of eight major   Mangifera indica moderately inhibited  Potential for clinically important     Funding information  This research did not receive any specific grant from funding agencies in the public, commercial, or not\u2010for\u2010profit sectors Management of chronic diseases is burdensome to patients (Eton et\u00a0al., 2013; \u00d8rtenblad, Meillier, & J\u00f8nsson, 2017) who tend to seek alternative remedies to conventional medications that may supposedly provide cure or offer safe use (Yarney et\u00a0al., 2013; Joeliantina, Agil, Qomaruddin, Jonosewojo, & Kusnanto, 2016) This self\u2010medication practice is common among chronically ill patients or patients with terminal diseases (Bodenheimer, Lorig, Holman, & Grumbach, 2002; Hasan, Ahmed, Bukhari, & Loon, 2009), and the major culprit in this group of patients are dietary supplements and herbal medicines (Gardiner, Graham, Legedza, Eisenberg, & Phillips, 2006; Gardiner, Phillips, & Shaughnessy, 2008)."}, {"generated": ["for 12 weeks"], "gold": [], "text": "34860-2.5L-R) and ammonium acetate (catalog No."}, {"generated": ["for 12 weeks"], "gold": [], "text": "The following formula determines the half-maximal inhibitory concentration (IC SRM Medical College Hospital and Research Centre and SRM Institute of Science and Technology, Kattankulathur ethics committees approved the protocol (approval No."}, {"generated": ["for 14 days"], "gold": ["14 days"], "text": "The selected volunteers were randomized to placebo (inert substitute for a treatment or intervention) or MenoAct851 formulation (500 mg BID for 14 days in double-blind fashion) groups."}, {"generated": ["after 2 weeks"], "gold": [], "text": "Table 3  Platelet aggregation (Ohms) after 2 weeks of echinacea and policosanol pre-treatment (n= 12) \tControl\tPolicosanol treatment\tEchinacea treatment Agonist\tMean (95% CI)\tMean (95% CI)\tGeometric mean ratio to control (90% CI)\tMean (95% CI)\tGeometric mean ratio to control (90% CI) ADP*\t7.8 (5.5, 10.0)\t6.8 (4.9, 8.8)\t0.92 (0.64, 1.30)\t7.5 (4.1, 10.8)\t0.84 (0.59, 1.19) Arachidonic acid\t11.0 (9.6, 12.5)\t11.2 (9.4, 12.9)\t1.00 (0.82, 1.23)\t12.1 (9.3, 15.0)\t1.06 (0.86, 1.30) Collagen\t13.0 (11.5, 14.6)\t14.9 (12.6, 17.2)\t1.13 (0.93, 1.37)\t15.8 (12.2, 19.5)\t1.17 (0.97, 1.42) Open in a separate window *Adenosine diphosphate."}, {"generated": ["In vitro"], "gold": [], "text": "The IC It was not possible to determine the IC In vitro CYP assays offer an accurate, and relatively inexpensive, first stage assessment tool for gauging the potential for herb-drug interactions."}, {"generated": ["after 5 days"], "gold": [], "text": "Five days after presentation, her symptoms had completely resolved."}, {"generated": ["30 minutes", "Day 5"], "gold": [], "text": "At 30\u202fmin following the 8PM dose on Day 5, the rats were anesthetized and about 10\u202fmL of blood were collected from rats\u2019 inferior vena for determination of antiviral activity."}, {"generated": ["30 minutes", "Day 5"], "gold": [], "text": "At 30\u202fmin following the 8PM dose on Day 5, the rats were anesthetized and about 10\u202fmL of blood were collected from rats\u2019 inferior vena for determination of antiviral activity."}, {"generated": ["after co-administration"], "gold": [], "text": "This can further be verified by the lowered OSA/OS ratio in rat urine samples after co-administration with RS (Fig."}, {"generated": ["after co-administration with RS"], "gold": [], "text": "As shown in Table 1, after co-administration with RS, BIO of OS increased by 62% without change in its absorption rate (k  The developed pop-PK model lets us have an interpretation on the contradictory phenomena that co-administration of RS would increase both the elimination rate and systemic exposure (AUC The pop-PK model could separately estimate the metabolic clearance (CL  A platform including a six-dimension in-vitro screening, an in-vivo pharmacokinetics in rats and an ex-vivo pharmacodynamic evaluation, has been developed and successfully applied to find RS as a potential herb that would influence the co-administrated OS in rats."}, {"generated": ["11.5\u201313.5 min", "14\u201315 min", "0\u20138.5 min", "8.7\u201311 min"], "gold": [], "text": "The gradient elution program was as follows: 0\u20138.5\u00a0min, 97% A; 8.7\u201311\u00a0min, 60% A; 11.5\u201313.5\u00a0min, 10% A; 14\u201315\u00a0min, 97% A."}, {"generated": ["11.5\u201313.5 min", "14\u201315 min", "0\u20138.5 min", "8.7\u201311 min"], "gold": [], "text": "The gradient elution program was as follows: 0\u20138.5\u00a0min, 97% A; 8.7\u201311\u00a0min, 60% A; 11.5\u201313.5\u00a0min, 10% A; 14\u201315\u00a0min, 97% A."}, {"generated": ["11.5\u201313.5 min", "14\u201315 min", "0\u20138.5 min", "8.7\u201311 min"], "gold": [], "text": "The gradient elution program was as follows: 0\u20138.5\u00a0min, 97% A; 8.7\u201311\u00a0min, 60% A; 11.5\u201313.5\u00a0min, 10% A; 14\u201315\u00a0min, 97% A."}, {"generated": ["11.5\u201313.5 min", "14\u201315 min", "0\u20138.5 min", "8.7\u201311 min"], "gold": [], "text": "The gradient elution program was as follows: 0\u20138.5\u00a0min, 97% A; 8.7\u201311\u00a0min, 60% A; 11.5\u201313.5\u00a0min, 10% A; 14\u201315\u00a0min, 97% A."}, {"generated": ["previous study"], "gold": [], "text": "This increase is comparable with 24% increase found during low to moderate exercise intensities determined using an incremental protocol in our previous study [22]."}, {"generated": ["acutely", "after 12 weeks"], "gold": ["12 weeks"], "text": "Previous studies in human participants have shown promising effects of YM ingestion on metabolic rate and RER acutely [21], and after 12 weeks of ingestion, on blood lipid metabolites in healthy obese participants [11,21]."}, {"generated": ["acutely", "after 12 weeks"], "gold": ["12 weeks"], "text": "Previous studies in human participants have shown promising effects of YM ingestion on metabolic rate and RER acutely [21], and after 12 weeks of ingestion, on blood lipid metabolites in healthy obese participants [11,21]."}, {"generated": ["during exercise"], "gold": [], "text": "The BF% data indicated all females who took part were at the lower BF% percentile, indicating that they were physically active, with higher  Although the positive effects of YM on fat-loss outcomes during exercise are found only in single trials, future research could test the longitudinal YM effectiveness, especially when combining regular exercise training with YM treatment."}, {"generated": ["chronic"], "gold": [], "text": "Chronic use of ginseng on its own has been associated with manic psychosis [90]."}, {"generated": ["until April 2016"], "gold": [], "text": "The patient received tacrolimus-based immunosuppression until April 2016, and then the treatment was switched from tacrolimus to sirolimus due to evident tremors."}, {"generated": ["at that time"], "gold": [], "text": "At that time the serum creatinine level was 74.27\u2009\u00b5mol/L and was stable."}, {"generated": ["at that time"], "gold": [], "text": "At that time the serum creatinine level was 74.27\u2009\u00b5mol/L and was stable."}, {"generated": ["too short"], "gold": [], "text": "Second, the pretreatment period of Epimedium sagittatum extract might have been too short to identify the possible herbal drug effect."}, {"generated": ["over years"], "gold": [], "text": "Though non-pharmacological treatments are the main therapy for these patients, application of analgetic drugs is common, often over years."}, {"generated": ["short-term"], "gold": [], "text": "Short-term use of opioids for patients who cannot reach pain relief otherwise may occur, e.g., to bridge the time until surgical intervention."}, {"generated": ["every 2\u20133 days"], "gold": [], "text": "Another patient experienced liver injury after taking 500 mg leaf powder every 2\u20133 days as a laxative [117]."}, {"generated": ["for almost two millennia"], "gold": [], "text": "This herb has been in use for diabetic treatment for almost two millennia [72]."}, {"generated": ["in a concentration dependent manner"], "gold": [], "text": "In the in vitro study, Asafetida resin alcoholic extract inhibited the formation of DOR from DEX in a concentration dependent manner (Fig."}], "FN": [{"generated": ["for the past two decades"], "gold": ["the past two decades"], "text": "During the past two decades, the world has witnessed an increased rate of conventional medicines integrated with CAM for treatment."}, {"generated": ["30-minute preincubations"], "gold": ["30-minute"], "text": "Potential TDI of P450 enzyme activity by CAW-R61J was determined using the shift in IC50 values between 30-minute preincubations in the presence and absence of NADPH."}, {"generated": ["72 h"], "gold": ["for 72 h"], "text": "The material was allowed to extract for 72 h at room temperature during which supernatant was decanted every 24 h and the solid residue reconstituted in the same volume of purified water for the extraction process to be repeated."}, {"generated": ["in a week"], "gold": ["week"], "text": "Therefore, two simulation scenarios were used to evaluate the magnitude of any interaction, (AAP 1000 mg once daily + GGT 7680 mg once daily) and (AAP 1000 mg \u00d7 4 times daily + GGT 7680 mg once daily) in a week."}, {"generated": ["for 14 days"], "gold": ["14 subsequent days"], "text": "Daily before going to bed, participants took two tablets, with 500\u2009mg valerian extract each (extraction solvent ethanol 70%, valerenic acid content 5.51\u2009mg/tablet), for 14 subsequent days."}, {"generated": ["over 12 weeks", "after 15 days", "every 4 weeks"], "gold": ["12 weeks", "15 days"], "text": "Haloperidol (38\u2009mg/kg bw) was applied intramuscularly once every 4 weeks over 12 weeks beginning after 15 days of treatment with valerian [51]."}, {"generated": ["over 12 weeks", "after 15 days", "every 4 weeks"], "gold": ["12 weeks", "15 days"], "text": "Haloperidol (38\u2009mg/kg bw) was applied intramuscularly once every 4 weeks over 12 weeks beginning after 15 days of treatment with valerian [51]."}, {"generated": ["for 7 days"], "gold": ["7 days"], "text": "Subjects also received rifampin (600 mg) and clarithromycin (1000 mg) for 7 days as positive controls for CYP3A induction and inhibition, respectively."}, {"generated": ["hours", "after drug discontinuation", "months"], "gold": ["hours to months"], "text": "Although DIP can occur from hours to months after the beginning of treatment, Another typical feature of DIP is its reversibility after drug discontinuation."}, {"generated": [], "gold": ["women", "within the last year", "within 4\u00a0wk", "more than 10\u00a0h", "within 6\u00a0mo", "within 1\u00a0mo", "within 3\u00a0mo", "after 1\u00a0yr"], "text": "Meanwhile, the exclusion criteria were: 1) women who became menopausal from surgery or chemotherapy; 2) women who underwent hysterectomy; 3) women with a history of endometrial hyperplasia or endometrial, breast, or sex hormone\u2013related cancers; 4) women with uncontrolled hypertension (160/100\u00a0mmHg or higher); 5) women with uncontrolled diabetes mellitus (fasting blood sugar 180\u00a0mg/dL or higher, or cases of starting or changing medication due to diabetes within 3\u00a0mo); 6) uncontrolled thyroid patients; 7) women who have had severe migraines within the last year or who have been diagnosed with thromboembolism, cerebrovascular disease, or serious cardiovascular disease; 8) women with atypical uterine bleeding after 1\u00a0yr of menopause; 9) women who have taken sleep inducers, antidepressants, selective estrogen receptor modulators, antihyperlipidemic drugs, antithrombotic drugs (Aspirin, Warfarin, and Clopidogrel), bisphosphonates, or calcitonin within 4\u00a0wk; 10) women who have taken plant hormones (isoflavone, flaxseed, pomegranate, horseradish, white sorghum, red shamrock, and red ginseng products) in the form of supplements or medicines within 4\u00a0wk; 11) women who have continuously taken functional foods and herbal medicines that could affect bone health, blood lipid lipids (triglyceride and cholesterol), and blood circulation within 4\u00a0wk; 12) women who were administered female hormone formulations within 6\u00a0mo; 13) women with alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels exceeding 3 times the laboratory's normal upper limit; 14) women with creatinine levels exceeding 2 times the laboratory's normal upper limit; 15) women with a history of drug or alcohol abuse; 16) women who have performed intensive exercises (more than 10\u00a0h) within 3\u00a0mo; 17) women with hypersensitivity to the test drug or its ingredients; 18) women with clinically significant abnormalities based on mammographies or Pap smears (Category 0 or higher than 3 of Breast Imaging Reporting and Data System (BI-RADS)) is confirmed (in the case of BI-RADS Category 0, subject registration is possible after confirming additional test results; in the case of Pap smear, atypical squamous cell of undetermined significance can be registered); 19) women who have participated in other clinical trials within 1\u00a0mo of the start of the current study or who are planning to participate in another clinical trial during the study period; and, 20) in cases where the researchers decided that the subject is unsuitable to participate in this study."}, {"generated": [], "gold": ["women", "within the last year", "within 4\u00a0wk", "more than 10\u00a0h", "within 6\u00a0mo", "within 1\u00a0mo", "within 3\u00a0mo", "after 1\u00a0yr"], "text": "Meanwhile, the exclusion criteria were: 1) women who became menopausal from surgery or chemotherapy; 2) women who underwent hysterectomy; 3) women with a history of endometrial hyperplasia or endometrial, breast, or sex hormone\u2013related cancers; 4) women with uncontrolled hypertension (160/100\u00a0mmHg or higher); 5) women with uncontrolled diabetes mellitus (fasting blood sugar 180\u00a0mg/dL or higher, or cases of starting or changing medication due to diabetes within 3\u00a0mo); 6) uncontrolled thyroid patients; 7) women who have had severe migraines within the last year or who have been diagnosed with thromboembolism, cerebrovascular disease, or serious cardiovascular disease; 8) women with atypical uterine bleeding after 1\u00a0yr of menopause; 9) women who have taken sleep inducers, antidepressants, selective estrogen receptor modulators, antihyperlipidemic drugs, antithrombotic drugs (Aspirin, Warfarin, and Clopidogrel), bisphosphonates, or calcitonin within 4\u00a0wk; 10) women who have taken plant hormones (isoflavone, flaxseed, pomegranate, horseradish, white sorghum, red shamrock, and red ginseng products) in the form of supplements or medicines within 4\u00a0wk; 11) women who have continuously taken functional foods and herbal medicines that could affect bone health, blood lipid lipids (triglyceride and cholesterol), and blood circulation within 4\u00a0wk; 12) women who were administered female hormone formulations within 6\u00a0mo; 13) women with alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels exceeding 3 times the laboratory's normal upper limit; 14) women with creatinine levels exceeding 2 times the laboratory's normal upper limit; 15) women with a history of drug or alcohol abuse; 16) women who have performed intensive exercises (more than 10\u00a0h) within 3\u00a0mo; 17) women with hypersensitivity to the test drug or its ingredients; 18) women with clinically significant abnormalities based on mammographies or Pap smears (Category 0 or higher than 3 of Breast Imaging Reporting and Data System (BI-RADS)) is confirmed (in the case of BI-RADS Category 0, subject registration is possible after confirming additional test results; in the case of Pap smear, atypical squamous cell of undetermined significance can be registered); 19) women who have participated in other clinical trials within 1\u00a0mo of the start of the current study or who are planning to participate in another clinical trial during the study period; and, 20) in cases where the researchers decided that the subject is unsuitable to participate in this study."}, {"generated": [], "gold": ["women", "within the last year", "within 4\u00a0wk", "more than 10\u00a0h", "within 6\u00a0mo", "within 1\u00a0mo", "within 3\u00a0mo", "after 1\u00a0yr"], "text": "Meanwhile, the exclusion criteria were: 1) women who became menopausal from surgery or chemotherapy; 2) women who underwent hysterectomy; 3) women with a history of endometrial hyperplasia or endometrial, breast, or sex hormone\u2013related cancers; 4) women with uncontrolled hypertension (160/100\u00a0mmHg or higher); 5) women with uncontrolled diabetes mellitus (fasting blood sugar 180\u00a0mg/dL or higher, or cases of starting or changing medication due to diabetes within 3\u00a0mo); 6) uncontrolled thyroid patients; 7) women who have had severe migraines within the last year or who have been diagnosed with thromboembolism, cerebrovascular disease, or serious cardiovascular disease; 8) women with atypical uterine bleeding after 1\u00a0yr of menopause; 9) women who have taken sleep inducers, antidepressants, selective estrogen receptor modulators, antihyperlipidemic drugs, antithrombotic drugs (Aspirin, Warfarin, and Clopidogrel), bisphosphonates, or calcitonin within 4\u00a0wk; 10) women who have taken plant hormones (isoflavone, flaxseed, pomegranate, horseradish, white sorghum, red shamrock, and red ginseng products) in the form of supplements or medicines within 4\u00a0wk; 11) women who have continuously taken functional foods and herbal medicines that could affect bone health, blood lipid lipids (triglyceride and cholesterol), and blood circulation within 4\u00a0wk; 12) women who were administered female hormone formulations within 6\u00a0mo; 13) women with alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels exceeding 3 times the laboratory's normal upper limit; 14) women with creatinine levels exceeding 2 times the laboratory's normal upper limit; 15) women with a history of drug or alcohol abuse; 16) women who have performed intensive exercises (more than 10\u00a0h) within 3\u00a0mo; 17) women with hypersensitivity to the test drug or its ingredients; 18) women with clinically significant abnormalities based on mammographies or Pap smears (Category 0 or higher than 3 of Breast Imaging Reporting and Data System (BI-RADS)) is confirmed (in the case of BI-RADS Category 0, subject registration is possible after confirming additional test results; in the case of Pap smear, atypical squamous cell of undetermined significance can be registered); 19) women who have participated in other clinical trials within 1\u00a0mo of the start of the current study or who are planning to participate in another clinical trial during the study period; and, 20) in cases where the researchers decided that the subject is unsuitable to participate in this study."}, {"generated": [], "gold": ["women", "within the last year", "within 4\u00a0wk", "more than 10\u00a0h", "within 6\u00a0mo", "within 1\u00a0mo", "within 3\u00a0mo", "after 1\u00a0yr"], "text": "Meanwhile, the exclusion criteria were: 1) women who became menopausal from surgery or chemotherapy; 2) women who underwent hysterectomy; 3) women with a history of endometrial hyperplasia or endometrial, breast, or sex hormone\u2013related cancers; 4) women with uncontrolled hypertension (160/100\u00a0mmHg or higher); 5) women with uncontrolled diabetes mellitus (fasting blood sugar 180\u00a0mg/dL or higher, or cases of starting or changing medication due to diabetes within 3\u00a0mo); 6) uncontrolled thyroid patients; 7) women who have had severe migraines within the last year or who have been diagnosed with thromboembolism, cerebrovascular disease, or serious cardiovascular disease; 8) women with atypical uterine bleeding after 1\u00a0yr of menopause; 9) women who have taken sleep inducers, antidepressants, selective estrogen receptor modulators, antihyperlipidemic drugs, antithrombotic drugs (Aspirin, Warfarin, and Clopidogrel), bisphosphonates, or calcitonin within 4\u00a0wk; 10) women who have taken plant hormones (isoflavone, flaxseed, pomegranate, horseradish, white sorghum, red shamrock, and red ginseng products) in the form of supplements or medicines within 4\u00a0wk; 11) women who have continuously taken functional foods and herbal medicines that could affect bone health, blood lipid lipids (triglyceride and cholesterol), and blood circulation within 4\u00a0wk; 12) women who were administered female hormone formulations within 6\u00a0mo; 13) women with alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels exceeding 3 times the laboratory's normal upper limit; 14) women with creatinine levels exceeding 2 times the laboratory's normal upper limit; 15) women with a history of drug or alcohol abuse; 16) women who have performed intensive exercises (more than 10\u00a0h) within 3\u00a0mo; 17) women with hypersensitivity to the test drug or its ingredients; 18) women with clinically significant abnormalities based on mammographies or Pap smears (Category 0 or higher than 3 of Breast Imaging Reporting and Data System (BI-RADS)) is confirmed (in the case of BI-RADS Category 0, subject registration is possible after confirming additional test results; in the case of Pap smear, atypical squamous cell of undetermined significance can be registered); 19) women who have participated in other clinical trials within 1\u00a0mo of the start of the current study or who are planning to participate in another clinical trial during the study period; and, 20) in cases where the researchers decided that the subject is unsuitable to participate in this study."}, {"generated": [], "gold": ["women", "within the last year", "within 4\u00a0wk", "more than 10\u00a0h", "within 6\u00a0mo", "within 1\u00a0mo", "within 3\u00a0mo", "after 1\u00a0yr"], "text": "Meanwhile, the exclusion criteria were: 1) women who became menopausal from surgery or chemotherapy; 2) women who underwent hysterectomy; 3) women with a history of endometrial hyperplasia or endometrial, breast, or sex hormone\u2013related cancers; 4) women with uncontrolled hypertension (160/100\u00a0mmHg or higher); 5) women with uncontrolled diabetes mellitus (fasting blood sugar 180\u00a0mg/dL or higher, or cases of starting or changing medication due to diabetes within 3\u00a0mo); 6) uncontrolled thyroid patients; 7) women who have had severe migraines within the last year or who have been diagnosed with thromboembolism, cerebrovascular disease, or serious cardiovascular disease; 8) women with atypical uterine bleeding after 1\u00a0yr of menopause; 9) women who have taken sleep inducers, antidepressants, selective estrogen receptor modulators, antihyperlipidemic drugs, antithrombotic drugs (Aspirin, Warfarin, and Clopidogrel), bisphosphonates, or calcitonin within 4\u00a0wk; 10) women who have taken plant hormones (isoflavone, flaxseed, pomegranate, horseradish, white sorghum, red shamrock, and red ginseng products) in the form of supplements or medicines within 4\u00a0wk; 11) women who have continuously taken functional foods and herbal medicines that could affect bone health, blood lipid lipids (triglyceride and cholesterol), and blood circulation within 4\u00a0wk; 12) women who were administered female hormone formulations within 6\u00a0mo; 13) women with alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels exceeding 3 times the laboratory's normal upper limit; 14) women with creatinine levels exceeding 2 times the laboratory's normal upper limit; 15) women with a history of drug or alcohol abuse; 16) women who have performed intensive exercises (more than 10\u00a0h) within 3\u00a0mo; 17) women with hypersensitivity to the test drug or its ingredients; 18) women with clinically significant abnormalities based on mammographies or Pap smears (Category 0 or higher than 3 of Breast Imaging Reporting and Data System (BI-RADS)) is confirmed (in the case of BI-RADS Category 0, subject registration is possible after confirming additional test results; in the case of Pap smear, atypical squamous cell of undetermined significance can be registered); 19) women who have participated in other clinical trials within 1\u00a0mo of the start of the current study or who are planning to participate in another clinical trial during the study period; and, 20) in cases where the researchers decided that the subject is unsuitable to participate in this study."}, {"generated": [], "gold": ["women", "within the last year", "within 4\u00a0wk", "more than 10\u00a0h", "within 6\u00a0mo", "within 1\u00a0mo", "within 3\u00a0mo", "after 1\u00a0yr"], "text": "Meanwhile, the exclusion criteria were: 1) women who became menopausal from surgery or chemotherapy; 2) women who underwent hysterectomy; 3) women with a history of endometrial hyperplasia or endometrial, breast, or sex hormone\u2013related cancers; 4) women with uncontrolled hypertension (160/100\u00a0mmHg or higher); 5) women with uncontrolled diabetes mellitus (fasting blood sugar 180\u00a0mg/dL or higher, or cases of starting or changing medication due to diabetes within 3\u00a0mo); 6) uncontrolled thyroid patients; 7) women who have had severe migraines within the last year or who have been diagnosed with thromboembolism, cerebrovascular disease, or serious cardiovascular disease; 8) women with atypical uterine bleeding after 1\u00a0yr of menopause; 9) women who have taken sleep inducers, antidepressants, selective estrogen receptor modulators, antihyperlipidemic drugs, antithrombotic drugs (Aspirin, Warfarin, and Clopidogrel), bisphosphonates, or calcitonin within 4\u00a0wk; 10) women who have taken plant hormones (isoflavone, flaxseed, pomegranate, horseradish, white sorghum, red shamrock, and red ginseng products) in the form of supplements or medicines within 4\u00a0wk; 11) women who have continuously taken functional foods and herbal medicines that could affect bone health, blood lipid lipids (triglyceride and cholesterol), and blood circulation within 4\u00a0wk; 12) women who were administered female hormone formulations within 6\u00a0mo; 13) women with alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels exceeding 3 times the laboratory's normal upper limit; 14) women with creatinine levels exceeding 2 times the laboratory's normal upper limit; 15) women with a history of drug or alcohol abuse; 16) women who have performed intensive exercises (more than 10\u00a0h) within 3\u00a0mo; 17) women with hypersensitivity to the test drug or its ingredients; 18) women with clinically significant abnormalities based on mammographies or Pap smears (Category 0 or higher than 3 of Breast Imaging Reporting and Data System (BI-RADS)) is confirmed (in the case of BI-RADS Category 0, subject registration is possible after confirming additional test results; in the case of Pap smear, atypical squamous cell of undetermined significance can be registered); 19) women who have participated in other clinical trials within 1\u00a0mo of the start of the current study or who are planning to participate in another clinical trial during the study period; and, 20) in cases where the researchers decided that the subject is unsuitable to participate in this study."}, {"generated": [], "gold": ["women", "within the last year", "within 4\u00a0wk", "more than 10\u00a0h", "within 6\u00a0mo", "within 1\u00a0mo", "within 3\u00a0mo", "after 1\u00a0yr"], "text": "Meanwhile, the exclusion criteria were: 1) women who became menopausal from surgery or chemotherapy; 2) women who underwent hysterectomy; 3) women with a history of endometrial hyperplasia or endometrial, breast, or sex hormone\u2013related cancers; 4) women with uncontrolled hypertension (160/100\u00a0mmHg or higher); 5) women with uncontrolled diabetes mellitus (fasting blood sugar 180\u00a0mg/dL or higher, or cases of starting or changing medication due to diabetes within 3\u00a0mo); 6) uncontrolled thyroid patients; 7) women who have had severe migraines within the last year or who have been diagnosed with thromboembolism, cerebrovascular disease, or serious cardiovascular disease; 8) women with atypical uterine bleeding after 1\u00a0yr of menopause; 9) women who have taken sleep inducers, antidepressants, selective estrogen receptor modulators, antihyperlipidemic drugs, antithrombotic drugs (Aspirin, Warfarin, and Clopidogrel), bisphosphonates, or calcitonin within 4\u00a0wk; 10) women who have taken plant hormones (isoflavone, flaxseed, pomegranate, horseradish, white sorghum, red shamrock, and red ginseng products) in the form of supplements or medicines within 4\u00a0wk; 11) women who have continuously taken functional foods and herbal medicines that could affect bone health, blood lipid lipids (triglyceride and cholesterol), and blood circulation within 4\u00a0wk; 12) women who were administered female hormone formulations within 6\u00a0mo; 13) women with alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels exceeding 3 times the laboratory's normal upper limit; 14) women with creatinine levels exceeding 2 times the laboratory's normal upper limit; 15) women with a history of drug or alcohol abuse; 16) women who have performed intensive exercises (more than 10\u00a0h) within 3\u00a0mo; 17) women with hypersensitivity to the test drug or its ingredients; 18) women with clinically significant abnormalities based on mammographies or Pap smears (Category 0 or higher than 3 of Breast Imaging Reporting and Data System (BI-RADS)) is confirmed (in the case of BI-RADS Category 0, subject registration is possible after confirming additional test results; in the case of Pap smear, atypical squamous cell of undetermined significance can be registered); 19) women who have participated in other clinical trials within 1\u00a0mo of the start of the current study or who are planning to participate in another clinical trial during the study period; and, 20) in cases where the researchers decided that the subject is unsuitable to participate in this study."}, {"generated": [], "gold": ["women", "within the last year", "within 4\u00a0wk", "more than 10\u00a0h", "within 6\u00a0mo", "within 1\u00a0mo", "within 3\u00a0mo", "after 1\u00a0yr"], "text": "Meanwhile, the exclusion criteria were: 1) women who became menopausal from surgery or chemotherapy; 2) women who underwent hysterectomy; 3) women with a history of endometrial hyperplasia or endometrial, breast, or sex hormone\u2013related cancers; 4) women with uncontrolled hypertension (160/100\u00a0mmHg or higher); 5) women with uncontrolled diabetes mellitus (fasting blood sugar 180\u00a0mg/dL or higher, or cases of starting or changing medication due to diabetes within 3\u00a0mo); 6) uncontrolled thyroid patients; 7) women who have had severe migraines within the last year or who have been diagnosed with thromboembolism, cerebrovascular disease, or serious cardiovascular disease; 8) women with atypical uterine bleeding after 1\u00a0yr of menopause; 9) women who have taken sleep inducers, antidepressants, selective estrogen receptor modulators, antihyperlipidemic drugs, antithrombotic drugs (Aspirin, Warfarin, and Clopidogrel), bisphosphonates, or calcitonin within 4\u00a0wk; 10) women who have taken plant hormones (isoflavone, flaxseed, pomegranate, horseradish, white sorghum, red shamrock, and red ginseng products) in the form of supplements or medicines within 4\u00a0wk; 11) women who have continuously taken functional foods and herbal medicines that could affect bone health, blood lipid lipids (triglyceride and cholesterol), and blood circulation within 4\u00a0wk; 12) women who were administered female hormone formulations within 6\u00a0mo; 13) women with alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels exceeding 3 times the laboratory's normal upper limit; 14) women with creatinine levels exceeding 2 times the laboratory's normal upper limit; 15) women with a history of drug or alcohol abuse; 16) women who have performed intensive exercises (more than 10\u00a0h) within 3\u00a0mo; 17) women with hypersensitivity to the test drug or its ingredients; 18) women with clinically significant abnormalities based on mammographies or Pap smears (Category 0 or higher than 3 of Breast Imaging Reporting and Data System (BI-RADS)) is confirmed (in the case of BI-RADS Category 0, subject registration is possible after confirming additional test results; in the case of Pap smear, atypical squamous cell of undetermined significance can be registered); 19) women who have participated in other clinical trials within 1\u00a0mo of the start of the current study or who are planning to participate in another clinical trial during the study period; and, 20) in cases where the researchers decided that the subject is unsuitable to participate in this study."}, {"generated": ["after 1-week"], "gold": ["1-week"], "text": "Plasma concentration-time profiles of the ginsenosides (A) Rb1, (B) Rb2, (C) Rc, (D) Rd, (E) PPD, and (F) PPT in the rat plasma after 1-week repeated administration of red ginseng extract (RGE)."}, {"generated": ["\u00b11 day"], "gold": ["\u00b11\u00a0day"], "text": "For each visit, a deviation of\u00a0\u00b11\u00a0day was permitted."}, {"generated": ["for 8 days"], "gold": ["for 8\u00a0days"], "text": "The following treatments were administered for 8\u00a0days each: placebo twice daily (treatment A), EGb 761\u00ae 120\u00a0mg twice daily (treatment B), and EGb 761\u00ae 240\u00a0mg in the morning and placebo in the evening (treatment C)."}, {"generated": ["sufficient to eventually induce", "1 week"], "gold": ["1\u00a0week"], "text": "A maximum exposure was realized with a 240-mg EGb 761\u00ae daily dose, and exposure duration was sufficient to eventually induce CYPs, as steady state for EGb 761\u00ae components was reached, and 1\u00a0week is typically sufficient to achieve full induction [35]."}, {"generated": ["over an 8-day period"], "gold": ["8-day period"], "text": "does not affect CYP2C19 activity when administered over an 8-day period."}, {"generated": [], "gold": ["for thousands of years"], "text": "Herbs have been used for primary health care for thousands of years before the advent of modern medicines."}, {"generated": ["approximately 15 minutes"], "gold": ["15 min"], "text": "After administration, aspirin is rapidly hydrolyzed in the body with an elimination half-life of approximatly 15 min [11,12]."}, {"generated": ["after 12 weeks"], "gold": ["12 weeks"], "text": "Resting lactate level was measured at baseline and after 12 weeks, and results are presented in Figure 2."}, {"generated": ["15 days"], "gold": ["15 day"], "text": "One brief 15 day study reported a significant increase in total cholesterol among hypertensive patients administered HS [18]."}, {"generated": [], "gold": ["30 days"], "text": "Female volunteers were excluded if they were pregnant (positive test for serum human chorionic gonadotropin at screening or check-in), breastfeeding, or planning to conceive a child within 30 days of treatment cessation."}, {"generated": ["for 14 days"], "gold": ["14 days"], "text": "The selected volunteers were randomized to placebo (inert substitute for a treatment or intervention) or MenoAct851 formulation (500 mg BID for 14 days in double-blind fashion) groups."}, {"generated": [], "gold": ["for thousands of years"], "text": "Jiawei Xiaoyao San (JWXYS) is a very common Chinese herbal formula used by the Chinese for thousands of years (Chen et al., 2014)."}, {"generated": ["acutely", "after 12 weeks"], "gold": ["12 weeks"], "text": "Previous studies in human participants have shown promising effects of YM ingestion on metabolic rate and RER acutely [21], and after 12 weeks of ingestion, on blood lipid metabolites in healthy obese participants [11,21]."}]}